Biomarkers of one-carbon metabolism and B-vitamin status : Targeted metabolomics in rats and humans exploring the effects of PPARα-activation and dietary composition by Lysne, Vegard
Vegard Lysne
Biomarkers of one-carbon
metabolism and B-vitamin status
Targeted metabolomics in rats and humans exploring the effects of PPARα-
activation and dietary composition
2019
Thesis for the degree of Philosophiae Doctor (PhD)
University of Bergen, Norway
at the University of Bergen
The material in this publication is covered by the provisions of the Copyright Act.
Print:     Skipnes Kommunikasjon / University of Bergen
 3
Scientific environment 
The project culminating in this thesis was carried out from September 2015 to June 
2019 at Centre for Nutrition, Department of Clinical Science, Faculty of Medicine, 
University of Bergen. My main supervisor was professor Ottar Kjell Nygård, and my 
co-supervisors were professor Jutta Dierkes, professor Per Magne Ueland and 
Dr. Elin Strand. The project was conducted in joint collaboration with the Department 
of Heart Disease, Haukeland University Hospital and Bevital AS. 
Funding has been provided by the University of Bergen in terms of a 4-year full time 
PhD scholarship. I also participated in the Postgraduate School of Clinical Medicine 
Research at the Department of Clinical Medicine and the National research school in 
population based epidemiology (EPINOR) 
 4
Acknowledgements 
The credit for this thesis does not only belong to me, but also to a long list of fantastic 
people who contributed in one way or another. Each and everyone of you have been 
deciding factors in the completion of this project. 
The help and support from my supervisors has been invaluable. I am deeply 
indebted to my main supervisor, professor Ottar Nygård. You really are a true 
academic at heart! Your creativity, open-mindedness, and enthusiasm can only be 
admired. The academic world needs people like you, who are willing to push 
boundaries and challenge established “truths”. I am forever grateful for all the time 
and resources you have invested in me. I would also like to extend my deepest 
gratitude to my co-supervisors, professor Jutta Dierkes, professor Per Magne Ueland 
and Dr Elin Strand, for your continuous guidance, support and encouragement. You 
were always available when I needed you, and your thorough feedback has improved 
every part of this thesis, as well as making the whole process more enjoyable. 
To all my current and former colleagues. Without all of you, writing this thesis 
would have been a much less pleasant experience. I am honored to call you my 
friends! Many thanks to my colleagues at the Centre for Nutrition for making 
important contributions to my day-to-day quality of life. We even organized a 
conference together, an experience I will remember for a long time! Hanne, you 
really are the best office mate anyone can ask for. Your effort to keep me focused on 
the thesis, when my mind wanted to do everything else (which was all the time), was 
absolutely crucial! To my colleagues at the Preventive Cardiology group and at 
Bevital, I am extremely grateful for all the fantastic trips we have had together, 
forming memories I will cherish forever.  
Special thanks to Thomas, my partner in crime and close friend, who I have 
been working alongside since our master theses. Even though we went different ways 
for our PhDs we are still in daily contact, and our collaboration will definitely 
continue in the future.  
 5
To all my friends outside work, thank you for providing happy distractions to 
take my mind of work when needed.  
I wish to thank the most supporting family anyone could ask for. My parents, 
Anne Sofie and Dan, you have always shown interest in whatever I have decided to 
do, and given me your fullest support. Torbjørn, you bring out my competitive side 
and always remind me that we don’t settle for second best. 
Last, but definitely not least, many thanks to my girlfriend Andrea. Thank you 
for always challenging me, and for reminding me that there are more important things 
to life than one-carbon metabolism and B-vitamins! You bring out the best in me, and 
I really look forward to spending less time at the office and more time at home in the 
wake of writing this thesis. Honorable mentions go to our cat William, who 
throughout the work with this thesis has done his best to increase the sample size for 





Bergen, June 2019 
 6
Abbreviations 
3Rs the three R’s (Reduction, Replacement, Refinement) 
ACMS 2-amino-3-carboxymuconate semialdehyde 
ACMSD 2-amino-3-carboxymuconate semialdehyde dehydrogenase 
ALP Alkaline phosphatase 
AMI Acute myocardial infarction 
BHMT Betaine-homocysteine methyltransferase 
CAD Coronary artery disease 
CBS Cystathionine β-synthase 
CGL Cystathionine γ-lyase 
CVD Cardiovascular disease 
DAG Directed Acyclic Graph 
DMG Dimethylglycine 
DMGDH Dimethylglycine dehydrogenase 
FAD Flavin adenine dinucleotide 
FFQ Food Frequency Questionnaire 
FMN Flavin mononucleotide 
gMean Geometric mean 
GNMT Glycine-N-methyltransferase 
gSD Geometric standard deviation 
 7
Hcy Homocysteine 
LOESS Locally estimated scatterplot smoothing 
MMA Methylmalonic acid 
mNAM 1-methylnicotinamide 
MS Methionine synthase 
mTHF 5-methyltetrahydrofolate 
MTHFR Methylenetetrahydrofolate reductase 
MUFA Monounsaturated fatty acids 
NAD Nicotinamide dinucleotide 
NAM Nicotinamide 
NNMT Nicotinamide methyltransferase 
PA 4-Pyridoxic acid 
PAr Pyridoxic acid index, PA/(PL+PLP) 
PI Prediction interval 
PL Pyridoxal 
PLP Pyridoxal-5-phosphate 
PPAR Peroxisome proliferator-activated receptor 
PPRE PPAR responsive elements 
PUFA Polyunsaturated fatty acids 





SAP Stable angina pectoris 
SARDH Sarcosine dehydrogenase 
SFA Saturated fatty acids 
SHMT Serine hydroxymethyltransferase 
SMD Standardized mean difference 
tHcy Total Homocysteine 
TTA Tetradecylthioacetic acid 




One-carbon metabolism is an overarching term describing central metabolic 
pathways involved in the transfer of one-carbon units. These include the methionine-
homocysteine and folate cycles, as well as the choline oxidation and transsulfuration 
pathways, all of which depend on B-vitamins as cofactors. Circulating concentrations 
of several metabolites and intermediates of these metabolic pathways have been 
linked to chronic disease risk. Thus, extending our knowledge regarding the 
regulation of these pathways is warranted.  
Targeted metabolomics offers the opportunity to study the concentration of 
several metabolites of these pathways simultaneously, and is thus required for the 
thorough investigation of the effects of diet and other factors on one-carbon 
metabolism. Diet provides both substrates, cofactors and one-carbon units, 
influencing the complex regulation of the different metabolic pathways. Furthermore, 
of particular interest is the activation of the nuclear receptor PPAR (peroxisome 
proliferator-activated receptor) α, a lipid sensor involved in the regulation of energy 
metabolism. The overall aim of this thesis was to utilize targeted metabolomics to 
explore the effect of PPARα-activation and dietary composition on of one-carbon 
metabolism and B-vitamin status. The effect of pharmacological PPARα-activation 
was addressed in Paper I and II, taking advantage of studies in laboratory animals. In 
Paper III, the effect of dietary macronutrient composition was investigated in a cross-
sectional analysis of a human cohort.  
METHODS: 
Animal models: We utilized data from two animal experiments, where male Wistar 
rats were treated with PPAR-agonists. In the first experiment, the rats received a pan-
PPAR-agonist for 50 weeks. In the second experiment, specific PPARα and γ- 
agonists were administered for 12 days. In both studies, plasma concentrations of 
metabolites were compared between treated and control animals. 
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Human study: This was a cross-sectional analysis in a cohort of 1928 patients with 
stable angina pectoris. Dietary data was derived from a food frequency questionnaire, 
and associations between dietary composition and plasma metabolite concentrations 
were assessed with multiple linear regression analyses. 
In all studies, plasma one carbon metabolites and B-vitamin markers were quantified 
by applying mass spectrometric methods. 
RESULTS: 
Long-term (Paper I) and short-term (Paper II) pharmacological PPARα-activation 
influenced the one-carbon metabolome, with the strongest effects seen for increased 
plasma concentration of nicotinamide and methylnicotinamide (vitamin B3), 
pyridoxal (vitamin B6), methylmalonic acid (marker of vitamin B12 status), 
dimethylglycine and glycine (choline oxidation pathway metabolites), and reduced 
flavin mononucleotide (vitamin B2). 
In humans, the observed effects of macronutrient intake were strongest for 
protein, where increased intake was associated with higher plasma concentrations of 
pyridoxal, pyridixal-5-phosphate and pyridoxic acid (vitamin B6), vitamin B12, 
riboflavin (vitamin B2) and methylnicotinamide. Further, we observed inverse 
associations between protein intake and plasma homocysteine and methylmalonic 
acid concentrations. When modeling the substitution of saturated with 
polyunsaturated fatty acids, we observed higher methylnicotinamide, pyridoxal, 
pyridixal-5-phosphate, cobalamin and dimethylglycine, as well as lower riboflavin 
concentrations. 
CONCLUSION AND IMPLICATION: 
PPARα-activation and dietary macronutrient composition altered the concentration of 
circulating biomarkers of one carbon metabolism. The effects of PPARα-activation 
were consistent across different conditions, and our results strongly suggest a central 
role for PPARα in the regulation of these metabolic pathways. Estimated effects of 
substituting saturated with polyunsaturated fatty acids yielded associations with the 
biomarkers similar to those observed with PPARα-activation in the animal studies. 
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This suggests that the effects of diet on one-carbon metabolism, especially related to 
dietary fatty acid composition, may be partly mediated through altered PPARα-
activity. 
This is the first metabolomic investigation targeting the majority of the 
metabolites of the one-carbon metabolism pathways simultaneously. Linking 
mechanistic studies in animals with observational data in humans provides novel 
information regarding metabolic regulations. The current investigations extend our 
understanding of how PPARα-activation and dietary composition influences the one-
carbon metabolome. Application to the human situation will offer potential for more 
individualized dietary advice. 
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1.1 One-carbon metabolism 
One-carbon metabolism is an overarching term collectively referring to the multitude 
of metabolic reactions involving the transfer of one-carbon units, molecules 
containing one carbon atom. These metabolic pathways are central in the regulation 
of many cellular processes, and is involved in the pathogenesis of several major 
lifestyle diseases. Thus, the regulation of these pathways is crucial to maintain health. 
Transmethylation is a key reaction of one-carbon metabolism, where a methyl 
group is transferred from a methyl donor to a methyl acceptor. Transmethylation is 
involved in both synthesis and modifications of a large variety of molecules 
throughout the body. Metabolic pathways central to the one-carbon metabolism 
include the methionine-homocysteine cycle, the transsulfuration pathway, the folate 
cycle and the choline oxidation pathway. Figure 1 provides an overview of the 
metabolic pathways discussed in this thesis, with key enzymes and their B-vitamin 
cofactors. 
1.1.1 The methionine-homocysteine cycle and transsulfuration 
Homocysteine (Hcy) is a sulfur-containing amino acid formed during 
transmethylation reactions from the essential amino acid methionine (1). The main 
methyl donor for these reactions is S-adenosyl-methionine (SAM), which is derived 
through adenosylation of methionine, by transferring an adenosyl group from 
adenosine triphosphate, in a reaction catalyzed by methionine adenosyltransferase 
(EC 2.5.1.6) (2). The various methyltransferases subsequently facilitate the transfer of 
the methyl group from SAM to the methyl accepting molecule, leaving S-
adenosylhomocysteine (SAH) (3), which is further hydrolyzed into Hcy (4). 
Synthesis of creatine and phosphatidylcholine are believed to be the major sources for 
Hcy production (5). Excess Hcy in the cells may be exported out into the blood. In 
the circulation, most Hcy is found bound to protein, as a disulfide with other sulfur  
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Figure 1. Overview of the metabolic pathways discussed: A) The folate cycle, B) the 
homocysteine-methionine cycle, C) the transsulfuration pathway and D) the choline 
oxidation pathway. The bold metabolites are measured in this project. Enzymes are shown 
in grey boxes and the B-vitamin cofactors in circles. In the folate cycle, a one-carbon unit is 
transferred to THF, forming mTHF via MTHF. mTHF donates the methyl group to Hcy, which 
is remethylated to Met in the homocysteine-methionine cycle, where Hcy is formed during 
transmethylation reactions. Hcy can be irreversibly catabolized to cysteine through the 
transsulfuration pathway. The choline oxidation pathway consists of the reactions 
metabolizing choline, and includes the transfer of a methyl group from betaine to Hcy, in a 
second remethylation pathway. This reaction also yields DMG, which is further metabolized 
in the mitochondrion. BADH, betaine aldehyde dehydrogenase; CBS, Cystathionine-β-
synthase; CGL, cystathionine-γ-lyase; CHDH, Choline dehydrogenase; DMG, 
dimethylglycine; DMGDH, DMG dehydrogenase; GNMT, Glycine N-methyltransferase; Hcy, 
homocysteine; Met, methionine; MS, methionine synthase, mTHF, 5-methyltetrahydrofolate; 
MTHF; 5,10-methylenetetrahydrofolate MTHFD1, methylenetetrahydrofolate dehydrogenase 
complex 1; MTHFR, methylenetetrahydrofolate reductase; Methyltransferases; SAH, S-
adenosylhomocysteine; SAM, S-adenosylmethionine; SARDH, Sarcosine dehydrogenase; 
SHMT, serine hydroxymethyltransferase; THF, tetrahydrofolate. 
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compounds, and minor amounts as free Hcy. When measuring circulating Hcy, it is 
mostly common to measure the total Hcy (tHcy) concentration, which includes all 
forms. Elevated tHcy is labeled hyperhomocysteinemia (6). When tHcy increases, 
two Hcy molecules can condensate to form homocystine, which can be subsequently 
excreted in the urine, referred to as homocystinuria (7). 
Residing at a branch point of three metabolic pathways, Hcy has two main 
metabolic fates within the cells. It can be remethylated back to methionine, or 
irreversibly converted to cysteine through the transsulfuration pathway (1). 
Remethylation of Hcy to methionine occurs through either the cobalamin-dependent 
methionine synthase (MS; EC 2.1.1.13), using 5-methyltetrahydrofolate (mTHF) 
provided by the folate cycle as methyl donor (8–11), or through betaine-
homocysteine methyltransferase (BHMT; EC 2.1.1.5), using betaine from the choline 
oxidation pathway as methyl donor (12–14). Of importance, MS-mediated 
remethylation is dependent on MS reductase (EC 1.16.1.8) for its initial activation 
and sustained activity (15,16). Equal contribution to Hcy remethylation of the two 
remethylation pathways has been demonstrated under normal conditions (17). While 
MS is ubiquitously found throughout the human body, BHMT is mainly expressed in 
liver and kidney (18). The transsulfuration pathway consists of two vitamin B6-
dependent enzymes, mainly residing in the liver (18), converting Hcy to cysteine 
(19). First, cystathionine β-synthase (CBS; EC 4.2.1.22), catalyzes a condensation of 
Hcy and serine to form cystathionine (20–22). Second, cystathionine is further 
hydrolyzed to form cysteine by cystathionine γ-lyase (CGL; EC 4.4.1.1) (23,24). 
Thus, in most tissues Hcy must either undergo remethylation by MS, or be exported 
to be metabolized in other organs. 
The metabolic fate of Hcy is determined according to the situation and 
requirement, and the coordination between these three pathways is regulated 
according to the requirement of methionine conservation (17). The SAM:SAH-ratio 
is frequently used as a measure of cellular methylation capacity, which is 
homeostatically maintained through the regulation of various methyltransferases (25). 
When SAM accumulates, transmethylation enzymes are stimulated. Through 
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scavenging of excess SAM, as well as by producing SAH, which inhibits methylation 
reactions (26), hepatic glycine-N-methyltransferase (GNMT; EC 2.1.1.20) is regarded 
central in the regulation of the methylation capacity (27). SAM concentrations in the 
liver are mainly regulated by phosphatidylcholine synthesis via 
phosphatidyletanolamine N-methyltransferase (EC 2.1.1.17). However, when SAM 
accumulates, other routes of SAM removal are also activated, such as the potential 
for histone methylation (28). 
Catalytic activity of both remethylation enzymes is dependent on a zinc atom 
contained within the enzymes, which facilitates binding and activation of the Hcy 
molecule (29,30). CBS contains an iron-containing autoinhibitory domain which 
must be released for the enzymatic activity to occur (31,32). This leaves these three 
metabolic pathways susceptible to regulation by the redox potential of the cell. 
Cysteine has been demonstrated to be the limiting factor for the synthesis of our most 
abundant intracellular antioxidant glutathione. It has been demonstrated that cysteine 
derived from Hcy transsulfuration contribute to approximately half of the intracellular 
glutathione pool (33). Additionally, oxidation of the zinc-atoms of MS and BHMT 
inhibits their activity, limiting remethylation of Hcy in conditions of increased 
oxidative stress (34,35). SAM directly regulates several of the key Hcy-metabolizing 
enzymes (36). SAM accumulation inhibits the two remethylation pathways. First, 
MS-dependent remethylation is reduced by inhibiting methylenetetrahydrofolate 
reductase (MTHFR; EC 1.5.1.20), the enzyme responsible for mTHF production (37–
39). Second, SAM inhibits BHMT allosterically (40), although only at very high 
SAM concentrations (41). Further, SAM has been demonstrated to stimulate the 
removal of Hcy in the liver through the transsulfuration pathway by relieving the 
autoinhibitory domain of CBS (32,42–44). 
Dietary intake of methyl groups influence the partitioning between 
remethylation and transsulfuration (45,46), and also seems to play a role in the 
distribution between the two remethylation pathways (47–50). Altogether, the 
intracellular concentration of Hcy is determined by the rates of production, 
remethylation and transsulfuration. Circulating tHcy concentration is further 
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dependent on cellular release into the blood, uptake by other tissues and renal 
excretion. 
1.1.2 The folate cycle 
The folate cycle constitutes the intracellular metabolism of folate, which exists in the 
cells as a group of interconvertible cofactors, sharing a common structure. 
Throughout the folate cycle the different folate cofactor forms are produced and 
interconverted, using the reduced folate form tetrahydrofolate as backbone (51). 
Folate metabolism is uniquely linked to Hcy metabolism through MS, the only 
known enzyme able to accept the methyl group of mTHF (52). This reaction yields 
tetrahydrofolate, which can accept a one-carbon molecule from either formate via the 
trifunctional enzyme complex mehylenetetrahydrofolate dehydrogenase 1 (EC 
6.3.4.3, 3.5.4.9 and 1.5.1.5) (53,54), or from serine in a reversible reaction catalyzed 
by serine hydroxymethyltransferase (SHMT; EC 2.1.2.1). Both reactions may form 
5,10-methylenetetrahydrofolate, which is converted to mTHF by MTHFR. SAM 
binds to MTHFR and inhibits the activity, meaning mTHF production is enhanced in 
situations of low SAM and vice versa. This contributes to ensuring the requirement 
for methionine conservation by increasing the capacity for Hcy remethylation when 
SAM levels are low. Of importance, mTHF also allosterically inhibits GNMT activity 
(27). This provides a regulatory mechanism where increased SAM concentrations 
reduce mTHF levels, which subsequently releases the inhibition of GNMT. This 
facilitates scavenging of excess SAM. Indeed, it has been suggested that decreased 
Hcy synthesis through GNMT, and not increased remethylation, is the main 
explanation for the inverse association between folate status and tHcy (55). 
1.1.3 The choline oxidation pathway 
The choline oxidation pathway refers to the conversion of choline to glycine, through 
betaine, dimethylglycine (DMG) and sarcosine (56). Choline is a water-soluble 
quaternary ammonium compound mostly found incorporated into phospholipids as 
phosphatidylcholine. Choline may originate either from the diet or from endogenous 
synthesis by methylation of phosphatidyletanolamine to phosphatidylcholine (57). 
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This methylation occurs through phosphatidyletanolamine N-methyltransferase, and 
although ubiquitously expressed (18), its activity has been reported to primarily occur 
in the liver (56). Functions of choline are related to its effect on methylation capacity 
as a source of methyl groups as well as its involvement in hepatic lipid export (56). 
Further conversion of phosphatidylcholine to choline and phosphatic acid is catalyzed 
by phospholipase D (EC 3.1.4.4)(57). 
The first step of the choline oxidation pathway is conversion of choline to 
betaine within the mitochondrion. This happens in two steps, catalyzed by choline 
dehydrogenase (EC 1.1.99.1) and betaine aldehyde dehydrogenase (EC 1.2.1.8) 
(58,59). Like choline, betaine may also be found in the diet in addition to being 
synthesized endogenously from choline. Betaine has two main functions, as an 
osmolyte involved in cell volume regulation, and as the methyl donor for BHMT-
mediated remethylation of Hcy (60). The latter directly links the choline oxidation 
pathway to the methionine-Hcy cycle (Figure 1). In addition to methionine, the 
BHMT reaction also yields DMG (13). DMG diffuses back into the mitochondrion 
and is converted via sarcosine to glycine in two subsequent demethylation reactions, 
catalyzed by DMG dehydrogenase (DMGDH; EC 1.5.8.4) and sarcosine 
dehydrogenase (SARDH; EC 1.5.8.3), respectively (61). Both DMGDH and SARDH 
are mainly expressed in the liver and kidneys (18). Glycine may be reversibly 
interconverted with serine in a reaction catalyzed by SHMT, occurring both in the 
cytosolic (SHMT1) and mitochondrial (SHMT2) compartment (62,63). SHMT1 
primarily promotes serine synthesis, while SHMT2 promotes glycine synthesis (64). 
Serine may additionally be synthesized from intermediates of glycolysis, providing a 
link between the choline oxidation pathway and glucose metabolism (65). 
Glycine has several other fates. In the liver and pancreas (18), GNMT may 
convert glycine back to sarcosine in a SAM-dependent methylation reaction (66). As 
GNMT binds folate, it may also influence hepatic folate metabolism and folate-
dependent reactions (67). A third fate of glycine is catabolism through the 
nicotinamide adenine dinucleotide (NAD)-dependent trifunctional enzyme complex 
glycine cleavage system (EC 1.4.4.2, 2.1.2.10 and 1.8.1.4), yielding CO2, NH3, 
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NADH and a one-carbon group which enters the folate cycle (68). Both SHMT 
(especially cytosolic SHMT1) and glycine cleavage is sensitive to vitamin B6 status, 
and the activity decreases during deficiency (69,70). In addition to being a building 
block in protein synthesis, functions of glycine include being a precursor for creatine, 
purines, glutathione and heme (71). Creatine synthesis includes transmethylation by 
guanidinoacetate-N-methyltransferase (EC 2.1.1.2), which together with GNMT 
provides a role for glycine in Hcy production and the regulation of methylation 
capacity (5). 
1.1.4 Plasma one-carbon metabolites and disease risk 
In humans, one-carbon metabolites are only available in their transport organ, the 
blood. Elevated plasma tHcy is a well-established marker of increased 
atherothrombotic cardiovascular disease (CVD) and coronary heart disease risk (72). 
Additionally, plasma tHcy has been linked to several other clinical outcomes, 
including cancer (73), pregnancy complications (74), neural tube defects (75,76), 
congenital defects of the heart (77), osteoporosis (78), Alzheimer’s disease and 
dementia (79,80), depression (81), cognitive decline (82), hyperinsulinemia (83) and 
type 2 diabetes (84). However, although treatment with B-vitamins is an effective 
means of lowering plasma tHcy, secondary prevention of CVD through lowering 
tHcy with B-vitamins have largely failed to show clinical benefit (85). These 
observations have questioned the causal relationship, and suggest that elevated 
plasma tHcy perhaps should be regarded as a marker of underlying pathological 
mechanisms, rather than a risk factor per se (86). It also encourages the investigation 
into alternative explanations for the association between elevated plasma tHcy and 
adverse health outcomes, such as redox status. Indeed, the close relationship of 
methylation status and cellular redox signaling was recently referred to as 
Methoxistasis, and elevated tHcy was suggested to represent disturbances in this 
homeostasis (87). However, primary prevention with folic acid was shown to reduce 
the risk of ischemic stroke in a large, hypertensive Chinese cohort, without impacting 
mortality (88). They argued that the lack of benefit in prior trials could be due to their 
secondary preventive nature as well as being conducted in populations with high 
folate status contributing to a possible ceiling effect. 
 22
Plasma concentrations of metabolites along the choline oxidation and the 
transsulfuration pathways have been linked to risk of major life style diseases.  
 Elevated plasma choline concentrations has been associated with increased 
risk of cardiac events (89,90), acute myocardial infarction (91) and diabetes (92) 
among patients with established CVD. Both low and high plasma betaine 
concentrations have been linked to increased risk of cardiovascular events (93), while 
higher betaine concentration has been associated with a lower risk of colorectal 
cancer (94). In patients with established CVD, elevated plasma DMG has been 
associated with increased risk of acute myocardial infarction and mortality (95,96). 
Higher levels of sarcosine in the circulation has been associated with increased risk of 
prostate cancer (97), but the opposite has later been reported (98). In the 
transsulfuration pathway, plasma cystathionine has been associated with increased 
risk of acute myocardial infarction and mortality in patients with established CVD 
(99–101). Of interest, noncanonical reactions of both CBS and CGL yields the 
gaseous transmitter hydrogen sulphide (H2S), which has been shown to modulate 
several physiological functions related to disease risk (102). 
Glycine and serine metabolism have gained great attention for its role in 
cancer biology (65,103), and plasma glycine is inversely associated with acute 
myocardial infarction risk (104). Further, low plasma glycine concentrations have 
been observed in patients with obesity or diabetes type 2, and it also predicts diabetes 
type 2 incidence. Both weight loss and physical activity aimed at improving insulin 
resistance consistently lead to increased plasma glycine (105). 
1.2 B-vitamins and markers of B-vitamin status 
The B-vitamins are a heterogeneous group of essential water-soluble nutrients 
functioning as cofactors for enzymatic reactions in a myriad of physiological 
functions. Pathways in relation with one-carbon metabolism include enzymes 
requiring different B-vitamins as cofactors, as indicated in Figure 1. 
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1.2.1 Riboflavin 
Riboflavin is a natural flavin belonging to the isoalloxazines. Higher organisms 
cannot synthesize these molecules, hence riboflavin is an essential nutrient. In the 
diet, riboflavin is obtained primarily from dairy products, eggs, meat (especially 
organ meat) and from some vegetables. Riboflavin was the second compound 
designated as one of the B-vitamins, and is thus known as vitamin B2 (106). In 
plasma vitamin B2 mainly exists as free riboflavin, but after cellular uptake most of it 
is found as its two cofactor forms; flavin mononucleotide (FMN) and flavin adenine 
dinucleotide, of which the latter comprises ~90% of the total flavin in the body. FMN 
is formed from riboflavin by the zink-dependent riboflavin kinase (EC 2.8.1.26) (107) 
and flavin adenine dinucleotide is formed from FMN (108). The two flavocoenzymes 
act as cofactors for flavoproteins which primarily catalyze redox reactions. The 
flavocoenzymes are also involved in energy metabolism as well as the metabolism of 
other vitamins such as folate, vitamin B6 and cobalamin. As plasma concentrations of 
flavin adenine dinucleotide are tightly regulated and does not respond to changes in 
riboflavin status, circulating concentrations of riboflavin or FMN have been 
suggested as better alternatives to assess vitamin B2 status in epidemiological settings 
(109). 
1.2.2 Niacin 
Niacin refers to nicotinamide (NAM) and nicotinic acid, and is known as vitamin B3. 
Nicotinic acid and NAM serve as precursor for the essential molecule NAD, which is 
involved as cofactor or substrate for a vast number of reactions, primarily redox-
reactions. In energy metabolism, β-oxidation of fatty acids and substrate oxidation in 
the Krebs cycle is dependent on NAD+ as an electron carrier. Some enzymes in the 
metabolic pathways discussed in this thesis also depend on NAD+, such as MTHFR, 
betaine aldehyde dehydrogenase and MS reductase. Many NAD-dependent reactions 
yield NAM, which through the salvage pathway is recycled to NAD (110). Through a 
SAM-dependent methylation reaction catalyzed by nicotinamide-N-methyltransferase 
(NNMT, EC 2.1.1.1), NAM and nicotinic acid can be converted to N1-
methylnicotinamide (mNAM). mNAM has been suggested to carry cardioprotective 
properties, and its production may be another mechanism for scavenging of excess 
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SAM (111). Ideally, niacin status is measured by quantification of tissue NAD. 
However, as the half-life of plasma NAD is short, the measurement of the other 
biomarkers are used more frequently (110). 
Niacin is obtained from the diet as niacin, or through catabolism of the 
essential amino acid tryptophan via the kynurenine pathway. Food sources of niacin 
include dairy products, meat, fish, cereals, vegetables and peanuts. Total dietary 
niacin is measured in niacin equivalents, which also includes tryptophan as an NAD 
precursor (110). Most dietary tryptophan is catabolized through the kynurenine 
pathway (112,113). One of the end metabolites of this pathway is hydroxyanthranilic 
acid, which is further enzymatically converted to 2-amino-3-carboxymuconate 
semialdehyde (ACMS). In liver and kidney, ACMS may be catabolized to picolinic 
acid by the enzyme ACMS dehydrogenase (ACMSD; EC 4.1.1.45). When ACMS 
accumulates it may be non-enzymatically converted to quinolinic acid which through 
quinolinic acid phosphoribosyltransferase (QAPRT; EC 2.4.2.19) is a substrate for 
NAD synthesis. ACMSD and QAPRT are considered the rate-limiting enzymes for 
the tryptophan-to-NAD conversion, and inhibition of ACMSD has been shown to 
increase niacin synthesis (114,115). 
1.2.3 Vitamin B6 
Vitamin B6 collectively refers to six interconvertible compounds with a shared 
structure: pyridoxal (PL), pyridoxine, pyridoxamine and their phosphorylated forms. 
Several enzymes are involved in the regulation and interconversion between the 
different forms. The three primary B6-forms can be 5’- phosphorylated by PL kinase 
(EC 2.7.1.35) and the phosphorylated forms of pyridoxine and pyridoxamine is 
converted to PL-5-phosphate (PLP) by pyridoxine-5’-phosphate oxidase (EC 1.4.3.5) 
(70). Notably, this enzyme is a flavoprotein dependent on FMN as cofactor, which 
interconnects the metabolism of vitamin B2 and B6 (116). PLP is the active cofactor 
form of vitamin B6, serving as cofactor for more than 160 enzymatic reactions mostly 
involved in amino acid metabolism. Of relevance to this thesis, both enzymes of the 
transsulfuration pathway, as well as SHMT, depend on PLP as cofactor. In blood, 
vitamin B6 is mainly circulating as PLP (70-90%), and to a lesser degree as PL and 
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the catabolite 4-pyridoxic acid (PA). PLP is converted to PL by alkaline phosphatase 
(ALP; EC 3.1.3.1), which is necessary for uptake of B6 into the target cells, as the 
phosphorylated form cannot cross cell membranes. 
Vitamin B6 is found in a wide variety of foods, mainly bound to protein. 
Among the main sources are meat, fish and whole-grains. Vitamin B6 status may be 
assessed directly, by measuring the concentration of B6 forms in blood or urine, or 
indirectly by evaluation of the activity of PLP-dependent enzymes or measurement of 
metabolites dependent on such reactions. The most commonly used method of direct 
assessment is plasma PLP concentration. However, factors other than vitamin B6 
may have a strong influence on PLP concentrations, including inflammation and 
smoking (57), complicating the interpretation. Total circulating vitamin B6, as well as 
urinary excretion of PA, has been suggested as biomarkers (117), but the lack of 
evaluation criterions render these alternative measures less useful compared to 
plasma PLP. Several of the enzymes of the kynurenine pathway utilizes PLP as 
cofactor, and both the tryptophan loading test (117) and several ratios of kynurenine 
pathway metabolites have been suggested as functional markers (118). 
Systemic vitamin B6 status has received attention for its inverse association 
with oxidative stress and inflammation, maybe reflecting an increased demand for 
PLP during inflammation (119–121). Low plasma PLP has been associated with 
several inflammatory conditions, with a tissue-specific reduction of liver PLP 
suggesting a mobilization of B6 to sites of inflammation (70,122). The ratio of 
PA/(PL + PLP), termed the PAr-index (PAr) is a suggested marker of the B6 
catabolism during inflammation (123). 
1.2.4 Folate 
Folate is a generic term referring to a family of interconvertible coenzymes, as 
described in section 1.1.2. The term includes naturally occurring folates present in the 
reduced form, and synthetic folic acid found in supplements and fortified food 
products. Folic acid is reduced to tetrahydrofolate, and subsequently metabolized like 
the natural folates. Folate is found in a wide variety of foods, but among the main 
sources are green leafy vegetables, dark green vegetables and certain legumes such as 
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beans. However, in large parts of the world the main source is grain products due to 
mandatory fortification with folic acid (124). Folic acid is the oxidized and more 
stable form of the vitamin which is usually used for food fortification and in 
supplements. It also has higher bioavailability than natural folates. Women of 
reproductive age is recommended to supplement the diet with 400μg folic acid, as 
pre- and periconceptional supplementation has been shown to reduce the risk of 
neural tube defects (125). 
The different folate coenzyme forms are involved in the synthesis and 
modifications of cellular components like nucleotides and amino acids (124). In the 
circulation, folate is primarily found as mTHF (126). However, when the capacity to 
reduce folic acid is exceeded, which is observed to happen at a single daily dose of > 
200 μg (127), unmetabolized folic acid may appear in the circulation. This is 
frequently observed in populations consuming fortified foods (128,129), including 
pregnant women (130,131). However, although folic acid is not known to be a 
cofactor, there are currently no established associations between circulating 
unmetabolized folic acid and adverse events. Of particular relevance to the current 
thesis, is the role of mTHF as methyl donor for MS-mediated remethylation of Hcy. 
Folate supplementations effectively lowers circulating tHcy although this effect may 
be due to reduced Hcy production rather than increased remethylation (55). Further, 
expression of GNMT has been suggested to be a determinant of hepatic as well as 
plasma folate concentrations (67). 
1.2.5 Cobalamin 
Cobalamin (Vitamin B12) is a water-soluble micronutrient required as cofactor for 
two enzymatic reactions in higher animals such as humans. Methylcobalamin is 
cofactor for the cytosolic MS, involved in Hcy remethylation. Adenosylcobalamin is 
cofactor for the mitochondrial methylmalonyl-CoA mutase (EC 5.4.99.2) (132), 
catalyzing the catabolism of methylmalonyl-CoA, originating from the breakdown of 
branched-chained amino acids, odd-chained fatty acids and cholesterol, to succinyl-
CoA. Succinyl-CoA is a precursor for heme biosynthesis, as well as a substrate for 
energy production through Krebs cycle. Cobalamin deficiency may be related to 
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inadequate intakes, or acquired or inherited defects leading to disrupted absorption, 
processing or transport. The former is considered a nutritional deficiency, while the 
latter would be referred to as a functional deficiency. The ultimate manifestation of 
cobalamin deficiency is inhibition of MS and methylmalonyl-CoA mutase, leading to 
an accumulation of Hcy and methylmalonic acid (MMA), a dicarboxylic acid formed 
non-enzymatically from methylmalonyl-CoA (133). In the diet, we primarily find 
cobalamin in foods of animal origin, such as meat, fish, dairy and eggs. Milk has 
been suggested to be the most bioavailable source of cobalamin (134). In food 
cobalamin is primarily found as hydroxycobalamin, and supplemental cobalamin is 
commonly in the cyanocobalamin form. It has been suggested that as all cobalamin 
forms follow the same metabolic route, which form we consume makes little 
difference (135). However, recent experiments in rats suggest a possible difference in 
tissue distribution, which may potentially be of clinical relevance (136). 
Circulating status markers of vitamin B12 status include the static markers 
cobalamin and holo-transcobalamin, and the functional markers tHcy and MMA, 
which all have major weaknesses when utilized as standalone markers (132). 
Cobalamin is transported in the circulation bound to either transcobalamin or 
haptocorrin, whereof only the first is recognized by the transcobalamin receptors on 
the target cells. As most (~80%) of the circulating cobalamin is bound to haptocorrin, 
and thus not available for cellular uptake, total serum cobalamin is not necessarily 
reflective of status. Several studies have demonstrated discrepancies between 
circulating cobalamin and markers of cellular cobalamin status (137,138). Holo-
transcobalamin is a direct marker of the active fraction of circulating cobalamin, and 
is regarded as a more accurate measure of status compared to serum cobalamin. 
However, limited knowledge on the metabolism and homeostasis of this marker 
limits its use as a first line test (132). Circulating and urinary concentrations of the 
functional biomarkers tHcy and MMA can be utilized as indicators of cobalamin 
function. However, as remethylation of Hcy depends on both folate and cobalamin, 
tHcy is of limited value as a standalone marker of cobalamin status. Compared to 
tHcy, MMA is a more specific marker of cobalamin function, but it has been shown 
that only ~16% of the variation in plasma MMA is accounted for by vitamin B12, 
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age, sex and kidney function (143), suggesting that cobalamin-independent factors 
are playing a part in the regulation of MMA concentrations. Of interest, a genome-
wide investigation in healthy Irish adults identified two genetic variants which were 
strongly related to plasma MMA, the strongest being a single-nucleotide 
polymorphism in HIBCH which is involved in the catabolism of the branch-chained 
amino acid valine (144). 
1.3 Diet and one-carbon metabolism 
In addition to the direct link through intake of biomarkers, several published articles 
have suggested a role of dietary components in the regulation of one-carbon 
metabolism. Curtailing the intake of methyl groups through protein restriction was 
shown to increase the partitioning towards the two remethylation pathways (45,46). 
Short-term restriction of cysteine and methionine, while supplementing 
polyunsaturated fatty acids (PUFA), also altered the concentration of several 
metabolites, such as increased tHcy (145). Lower plasma tHcy were reported for 
increasing protein and PUFA intake, and at higher intakes of fish and eggs (146). In 
healthy volunteers, supplementation with krill oil rich in phosphatidylcholine and 
omega-3 PUFA reduced tHcy and increased the concentration of choline oxidation 
pathway metabolites (147). Further, in a metabolomic evaluation of a randomized 
controlled trial where ~6.5 E% from saturated fatty acids (SFA) was replaced by 
PUFA, several metabolites related to one-carbon metabolism differed between 
groups. Higher concentrations of glycine, serine, cystathionine and riboflavin, and 
lower concentrations of cysteine and cobalamin were observed in the intervention 
group (148). Total carbohydrate intake was positively associated with tHcy, while the 
opposite was seen with vegetables and whole-grain, indicating a role for carbohydrate 
quality (146). Indeed, whole-grain cereals are a main source of betaine (149), and 
higher intakes have been associated with higher plasma betaine (150). 
In rodents, increased intake of betaine, when combined with methionine 
restriction, has been reported to induce BHMT mRNA (151). Further, dietary fat 
increased the genetic expression of Choline dehydrogenase, BHMT and DMGDH, 
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and downregulated CBS and CGL, possibly promoting flux through the choline 
oxidation pathway and limit transsulfuration flux (152). The intake of glycine has 
been shown to impact both the conversion of glycine to serine through SHMT, and 
glycine catabolism through the glycine cleavage system, both of which were 
increased in rats receiving a glycine-supplemented diet (153). The intake of B-
vitamins also have an impact on one-carbon metabolism, as exemplified by the effect 
of folic acid and cobalamin on plasma tHcy (154). In mice, maternal protein 
restriction reduced the methylation of the PPARα-promoter, as well as increased 
expression of PPARα and several target genes in the offspring (155). 
1.4 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated nuclear 
hormone receptors, discovered on the basis of their activation by a class of rodent 
hepatocarcinogens causing proliferation of the peroxisomes (156). PPARs exist in 
three subclasses; PPARα, PPARγ and PPARβ/δ (157), which are all activated by a 
large variety of natural and synthetic ligands, including fatty acids and their 
derivatives (158,159). The PPARs are involved in the regulation of a myriad of target 
genes important for many physiological processes (157), and due to their important 
roles in lipid and glucose homeostasis they have been described as lipid and insulin 
sensors (158). PPARα has been described as a key nutritional sensor and central 
regulator of metabolic responses to dietary factors (160). 
A common feature of the PPARs is the requirement of forming a 
heterodimeric complex with the retinoid-X-receptor (RXR) before binding to PPAR 
responsive elements (PPRE) on target genes (161,162). This heterodimer is 
considered permissive, meaning the complex may also to some degree be activated 
by RXR-ligands (163). The three subtypes share a high degree of homology, but their 
functions are subtype specific, with large differences in ligand specificity and tissue 
distribution. PPARα augments fatty acid catabolism and apolipoprotein synthesis, and 
is ubiquitously expressed in tissues with high rates of fat oxidation, such as liver, 
brown adipose tissue, heart, skeletal muscle and kidneys. PPARγ is mainly expressed 
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in adipose tissue where its activation stimulates adipocyte differentiation and lipid 
storage, but also in heart and liver (157). PPARα-agonists like fibrates have been 
used to improve dyslipidaemia, and PPARγ-agonists, like thiazolidinediones and 
glitazones, have been used to improve insulin resistance (158). PPARβ/δ is 
ubiquitously expressed, and mainly promotes fatty acid oxidation in the 
mitochondrion (162). Of the PPARs, PPARα is most relevant for this thesis, and is 
therefore discussed in more detail in the following section. 
1.4.1 PPARα 
PPARα is involved in the regulation of many important biological processes in the 
cells, and a vast amount of target genes have been identified (164). PPARα is a key 
regulator of energy metabolism (160), and has mainly been known for its role in 
upregulating genes responsible for microsomal, peroxisomal and mitochondrial β-
oxidation (165,166). Additionally, PPARα plays a role in the regulation of 
carbohydrate and amino acid metabolism. PPARα upregulates gluconeogenetic and 
downregulate glycolytic genes (167), facilitating the continuous supply of glucose to 
glucose-dependent tissues like the brain during conditions of limited glucose 
availability. A possible mechanism underlying PPARα-mediated reduction in glucose 
utilization is inactivation of pyruvate dehydrogenase (EC 1.2.1.51) in numerous 
tissues (168). In amino acid metabolism, PPARα activation mainly suppresses amino 
acid degradation (169–171), with the exception of branch-chained amino acids where 
fibrate treatment was demonstrated to increase catabolism (172). In addition to being 
involved in the regulation of energy metabolism, PPARα-activation has been shown 
to reduce both inflammation and oxidative stress (173–178). 
Regulation of metabolic homeostasis 
Of particular interest, PPARα governs the shift in fuel utilization in response to the 
fasting state, by regulating genes necessary to increase hepatic oxidation of fatty 
acids, stimulate gluconeogenesis, glycogenolysis and ketogenesis, as well as 
minimizing amino acid breakdown (168). When fasted, PPARα-null mice suffer from 
metabolic abnormalities such as hypoglycemia, hypoketonemia as well as developing 
fatty liver due to diversion of lipids towards triglyceride synthesis (168). The hepatic 
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expression and activation of PPARα follows a diurnal rhythm inversely related to 
feeding status and is increased during fasting (179,180). The hepatic protein level 
correlates strongly with the genetic expression, but the increase in target genes is 
dependent on the presence of a PPARα ligand (180). It was previously suggested that 
fatty acids released from adipose tissue acted as ligands. However, it has been shown 
that only fatty acids provided by diet or produced in the liver, not those released from 
adipose tissue and transported as albumin bound free fatty acids, are able to activate 
hepatic PPARα (167,181). 
Dietary activation of PPARα 
Diet is directly linked to PPARα activation through supplying dietary fatty acids and 
its derivatives (182). Long-chained omega-3 polyunsaturated fatty acids (PUFA) and 
oxidized fatty acids are the most potent activators (158,168). Thus, it has been 
suggested that both amount and composition of dietary fatty acids may be of 
relevance when considering dietary influence on PPARα-activity (168). In mice, both 
high-fat feeding (152,183) and betaine supplementation (184) have been 
demonstrated to upregulate the expression of PPARα and its target genes, an effect 
suggested to possibly be mediated through increased BHMT flux (152,184). 
Based on the observation that PPARα is induced in the fasting state, as well as 
dietary fats acting as activators, ketogenic diets are of particular interest. Ketogenic 
diets are very low in carbohydrates, and correspondingly high in fat, which 
metabolically mimics fasting in terms of fuel utilization. Higher proportion of PUFA 
in the diet could potentially lead to stronger PPARα-activation (168). Indeed, while 
low-carbohydrate diets with high proportions of saturated fat (SFA) typically 
increases circulating lipid levels compared to low-fat diets (185), this was not 
observed with a ketogenic diet low in saturated fatty acids (SFA) (186), potentially 
reflecting stronger PPARα-activation by the latter diet. 
Pharmacological activation of PPARα 
In addition to maintaining metabolic homeostasis by serving as a target for 
endogenous ligands, PPARα is a targeted by many synthetic ligands, including lipid 
lowering fibrate drugs, including fenofibrate, clofibrate and WY14,643. 
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Pharmacological activation of PPARα raises plasma high-density lipoprotein-
cholesterol and reduces triglyceride levels. Hence PPARα agonists have been used to 
improve the circulating lipid profile and reduce CVD risk (178,187). 
Tetradecylthioacetic acid (TTA) is a modified saturated fatty acid with 16 carbon 
atoms and a sulfur atom incorporated into the third carbon, making it resistant to 
breakdown through β-oxidation. TTA is known as a pan-PPAR agonist with a 
particular high affinity towards PPARα (182,188), and administering TTA increases 
the hepatic expression of PPARα target genes. TTA treatment also elicits effects on 
lipid metabolism similar to what is observed with fibrate treatment (189–192), 
protects against weight gain (193), and carries anti-inflammatory and anti-oxidative 
properties (189,190). By being resistant to mitochondrial β-oxidation, TTA has been 
suggested to further contribute to PPARα-activation by facilitating the accumulation 
of an endogenous ligand (182). 
1.4.2 Between-species differences in response to PPARα-
activation 
Although PPARα is ubiquitously expressed across mammalian species, some major 
quantitative and qualitative between-species differences must be addressed. First, 
PPARα-activation in rodents increases the number and size of liver peroxisomes as 
well as elevated expression of proinflammatory cytokines, ultimately resulting in 
hepatomegaly and liver carcinogenesis. Humans are responsive to the lipid-lowering 
effects of PPARα-activation, but not to the detrimental effects on the liver (194,195). 
Accordingly, rodents belong to the so-called proliferating species, while humans do 
not. There are several suggested mechanisms for the between-species differences in 
response to PPARα-agonists. One potential explanation is quantitative differences in 
expression level. The expression level of hepatic PPARα was previously thought to 
be lower in humans compared to rodents, but recent data suggests that expression 
levels are similar. However, humans partly produce a truncated and dysfunctional 
protein, which may explain some functional differences (166). However, in human 
hepatocytes overexpressing PPARα to the levels found in rodents, it was 
demonstrated that although the expression of other PPARα target genes were 
increased, markers of peroxisome proliferation were not affected (196). This suggests 
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that lack of detrimental effects on the liver is due to factors other than PPARα 
expression level. PPARα-null mice expressing human PPARα respond similarly to 
humans when exposed to PPARα-agonists, and do not develop liver cancer (197–
199). This indicates that human and rodent PPARα differ in their gene regulating 
profiles (200). A transcriptomic analysis of chimeric mice carrying human liver cells 
receiving treatment with a PPARα-agonist verified that PPARα play an important 
role in the regulation of lipid metabolism in the human liver. It also provided 
evidence that compared to mice, gene expression in human hepatocytes are in general 
less sensitive to PPARα-activation (201). Another potential source of differences in 
PPARα-activation in rodents compared to humans may be related to lipid transport, 
providing endogenous agonists. 
1.4.3 PPARα and one-carbon metabolism 
Several links have been demonstrated between PPARα activation and one-carbon 
metabolism. Treatment with fibrates has been consistently associated with increased 
tHcy in humans (202,203), and although the mechanism has not been fully 
elucidated, it has been suggested to be related to decreased kidney function (204). 
Indeed, fibrate treatment leads to an increase in some kidney function markers such 
as creatinine and cystatin C, but not others such as symmetric dimethylarginine 
(204,205). However, the increase in tHcy is preventable by co-administration of 
tHcy-lowering B-vitamins (206,207), suggesting that kidney function does not fully 
explain the observations. Based on animal and cell experiments, inhibition of Hcy 
catabolism through the transsulfuration pathway could be involved (170,208). 
Further, increased urinary excretion of choline, betaine and DMG has been observed 
both in humans (209–212) and animals (138,170), which may reflect upstream 
accumulation of metabolites due to PPARα-dependent downregulation of DMGDH 
and SARDH (170,213). Related to this, it has been suggested that the association 
between elevated plasma DMG and CVD risk may partly be related to enhanced 
endogenous PPARα-activity (95,96). 
Higher plasma concentrations of glycine and serine are other consistent findings 
when treating animals with PPARα-agonists (138,170,215,216). Based on metabolic 
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tracer experiments, increased plasma glycine was demonstrated to primarily be due to 
increased rate of appearance, rather than decreased removal, suggesting a role for 
PPARα in de novo synthesis of these amino acids (215). Reduced intracellular 
conversion to sarcosine through GNMT may also contribute to glycine accumulation, 
as PPAR α activation has been reported to inhibit hepatic GNMT on the gene and 
protein level (170,214). The previously published effects of PPARα-activation on the 
enzymes of the choline oxidation pathway are indicated in Paper II: Figure 1. 
When considering B-vitamin status, some consistent links have been 
demonstrated after PPARα-activation. Increased urinary excretion of NAM and 
mNAM has been reported repeatedly in animal experiments (138,170,216–218). 
Mechanistically, this has been shown to be caused by increased tryptophan-to-NAD 
conversion in the liver (220). Treatment of rodents with PPARα-agonists have been 
shown to reduce gene expession and enzymatic activity of ACMSD, as well as 
enhance the activity of QAPRT (170,208,217,219,221,222). This would contribute to 
increased partitioning of tryptophan catabolism towards NAD synthesis. PPARα-
activation has been demonstrated to upregulate ALP, the circulating enzyme 
responsible for the dephosphorylation of PLP to PL, providing a role for PPARα in 
the regulation of vitamin B6 status markers (217,219,223,224). Potential roles of 
PPARα in cobalamin metabolism include increased catabolism of odd-chained fatty 
acids and branch-chained amino acids, which both are yielding Succinyl-CoA, which 
is metabolized through methylmalonyl-Coenzyme A mutase. 
1.5 Knowledge gaps and rationale for this thesis 
As metabolites of the one-carbon metabolism are linked to the risk of major lifestyle 
diseases, unraveling their regulation is of interest both when considering treatment 
and prevention. Involvement of PPARα in the regulation of one-carbon metabolism 
has been demonstrated both on the gene and protein level. However, the regulatory 
role of PPARα has not been fully elucidated. Although some effects on the one-
carbon metabolome have been reported in the literature, a targeted analysis including 
the majority of the biomarkers has not been implemented. Many of the biomarkers of 
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interest in this thesis are provided by diet, and dietary composition has been linked to 
altered concentration of some one-carbon metabolites. Health effects of diet may 
partly be explained through effects on one-carbon metabolism, e.g. as suggested for 
the intake of whole grains (150). However, a targeted metabolomic approach to 
evaluate the associations between dietary composition and the one-carbon 
metabolome is lacking. 
Combining mechanistic data from animal studies and observational data in 
humans may fill knowledge gaps regarding the role of dietary composition in the 
regulation of one-carbon metabolism. This may in the future contribute to a 




This thesis concerns the intersection between three interrelated domains: One-carbon 
metabolism, PPARα-activation and diet. The overall aim was to utilize targeted 
metabolomics to explore the regulation of one-carbon metabolism and B-vitamin 
status. We hypothesized that pharmacological PPARα-activation, as well as changes 
in dietary composition would influence the activity in these metabolic pathways, and 
that this would be reflected by the one-carbon metabolome. We investigated these 
hypotheses using targeted metabolomics, first in animal studies and second in a 
cohort of patients with CVD. 
Specific aims 
• Paper I: Investigate the effect of a pan-PPAR agonist, primarily activating 
PPARα, on circulating and urinary concentration of one-carbon metabolites and 
systemic markers of B-vitamin status in male Wistar rats. (Published 2016) 
• Paper II: Investigate the effect of specific activation of PPARα and PPARγ on 
circulating concentrations of one-carbon metabolites and related markers of B-
vitamin status in male Wistar rats. (Submitted 2019) 
• Paper III: Explore the associations between dietary intake of carbohydrate, 
protein and fat on circulating one-carbon metabolites and markers of B-vitamin 
status in a cohort of patients with stable angina pectoris. (Manuscript ready for 
submission) 
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3. Materials and methods 
3.1 Quantification of outcome metabolites 
The outcome metabolites of interest were the same across the three included papers, 
namely metabolites related to Hcy metabolism, the choline oxidation pathway and 
markers of B-vitamin status. Study-specific analyses were carried out by the 
laboratory at Bevital AS (www.bevital.no), using automated methods based on mass-
spectrometry (225). The plasma metabolites were analyzed using gas- or liquid 
chromatography coupled with tandem mass spectrometry (226–228) or 
microbiological assay (229). Table 1 provides an overview of the outcome 
metabolites, the analytical quantification method used and which metabolites were 
included in each paper. The intraclass correlation coefficient is a descriptive statistic 
of within-person reproducibility, i.e. how representative a single measure is of long-
term average exposure. By expert agreement, an intraclass correlation coefficient < 












Table 1. Overview of outcome metabolites and analytical method across papers 
   Paper 
Plasma metabolite Analytical method ICC I II III 
Homocysteine metabolism     
Methionine GC-MS/MS 0.33 X X X 
Total homocysteine GC-MS/MS 0.72 X X X 
Cystathionine GC-MS/MS 0.63 X X X 
Cysteine GC-MS/MS 0.56 X X X 
Choline oxidation      
Choline LC-MS/MS 0.36 X X X 
Betaine LC-MS/MS 0.65 X X X 
Dimethylglycine LC-MS/MS 0.64 X X X 
Sarcosine GC-MS/MS 0.68   X 
Glycine GC-MS/MS 0.81 X X X 
Serine GC-MS/MS 0.71 X X X 
B-vitamin status markers     
Riboflavin LC-MS/MS 0.79 X X X 
Flavin mononucleotide LC-MS/MS 0.69 X X  
Nicotinamide LC-MS/MS N/A X X X 
1-methylnicotinamide LC-MS/MS N/A X X X 
Nicotinic acid LC-MS/MS N/A  X  
Pyridoxal LC-MS/MS 0.62 X X X 
Pyridoxal-5-phosphate LC-MS/MS 0.70 X X X 
Pyridoxic acid LC-MS/MS 0.58 X X X 
PA-ratio Calculated N/A  X X 
Folate Microbiological assay 0.56 X  X 
5-methyltetrahydrofolate LC-MS/MS N/A  X  
Cobalamin Microbiological assay 0.82 X X X 
Methylmalonic acid GC-MS/MS 0.81 X X X 
Source: www.bevital.no, data published in references 225-229. 
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3.2 Study design and statistical analyses 
To meet the aims of the thesis, three studies were performed. Table 2 summarize key 
characteristics of the included papers. 
Table 2. Key characteristics of the included papers 
 Paper I Paper II Paper III 
Species Rats Rats Humans 
(SAP patients) 
Study design Intervention Intervention Cross-sectional 
Sample size 20 20 1928 
Duration 50 weeks 12 days - 
Background diet Low-fat High-fat - 







intakes by FFQ 
Outcome Plasma and urine 
concentration of 










FFQ, food frequency questionnaire; PPAR, peroxisome proliferator-activated receptor; SAP, stable 




3.2.1 Paper I 
Study design 
Paper I was based on materials from a previous animal experiment (231), originally 
set out to investigate the effect of the pan-PPAR agonist TTA and/or fish oil on the 
incidence of ventricular cancer. A total of 210 male Wistar rats, aged 8 weeks on 
arrival, were initially obtained. Related to the primary aim of the study, the rats went 
through an initial surgical gastroenterostomy procedure, whereof 25 rats died. The 
remaining 185 rats were randomized into five experimental groups; 1) Low-fat diet, 
2) high-fat diet, 3) high-fat diet supplemented with TTA, 4) high-fat diet 
supplemented with fish oil and 5) high fat diet supplemented with fish oil and TTA. 
The rats were housed 5 per cage, and had free access to water and experimental diet 
for the study duration of 50 weeks. The animals were sacrificed under non-fasting 
conditions, after being anaesthetized by Isoflurane inhalation, and blood, urine and 
tissue were collected. After the publication of the original study, plasma and urine 
one-carbon metabolites and B-vitamins have been quantified in 10 animals per group. 
For this substudy, only rats from the high-fat control (n = 10) and high-fat with 
TTA (n = 10) groups were included. TTA was the exposure of interest, as it is known 
to be a pan-PPAR agonist with a particular high affinity towards the PPARα subtype 
(182,188). The experimental timeline is shown in Figure 2. 
The experiments complied with the Guidelines for the Care and Use of 
Experimental Animal use and the study protocols were approved by the Norwegian 
State Board for Biological Experiments with Living animals (“Forsøksdyrutvalget”, 




Figure 2. Flowchart illustrating the study design of the animal experiment in Paper I. 
Only rats from the HF and the HF + TTA groups were included in the statistical analyses. 
FO indicate fish oil; HF, High-fat; LF, Low-fat; TTA, tetradecylthioacetic acid. 
Statistical analyses and presentation of results 
Plasma and urinary metabolite concentrations were presented as arithmetic means 
with their standard deviations (SD). The urinary metabolites were standardized to 
urinary creatinine to correct for dilution. Correlations between plasma and urinary 
metabolites were assessed with Pearson’s correlations. Between-group differences 
were evaluated with independent samples t-tests, and effects were given as 
standardized mean differences (SMD)(95% confidence interval [CI]) which indicate 
differences in pooled SD units. The individual rat was considered the experimental 
unit of analysis. As we performed many tests, we used the procedure of Benjamini 
and Hochberg to calculate a cutoff for statistical significance at p<0.01 (232). 
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3.2.2 Paper II 
Study design 
Paper II was based on another previous animal experiment, the PPAR2014 study 
(233), designed to investigate the effects of short-term activation of PPARα and 
PPARγ on plasma lipids, fatty acid composition and gene regulation in liver and 
adipose tissue. In total, 20 male Wistar rats were block randomized to receive 
PPARα-agonist (WY-14,643) PPARγ-agonist (Roziglitazone) or placebo for a study 
period of 12 days. The animals received a standard low-fat chow diet, and a daily 
supplement of 300 μl muffin dough with or without the PPAR-agonist. The animals 
were housed 2-3 per cage, and all animals within the same cage belonged to the same 
intervention arm. However, the animals were taken out of the cages to receive the 
treatment, so for statistical analyses the individual rat was considered the 
experimental unit. The animals were weighed at day 0, 6, and 12, and food intake was 
estimated by weighing the food provided to the cages and subtracting residual feed 
after the experiment. Randomization was applied to all study phases; cage placement, 
all study procedures and termination. After receiving anesthesia with isoflurane, the 
animals were sacrificed under fasting conditions by cardiac puncture and 
exsanguination. Blood was collected in EDTA-tubes and centrifuged, and tissues 
harvested, before being snap-frozen and stored at -80°C until analyses. 
The experiment was conducted according to the Norwegian legislation and 
regulations governing experiments using live animals, and the protocol was approved 
by the Norwegian Committee for Experiments on Animals (FOTS ID: 2014/6187). 
Statistical analyses and presentation of results 
Plasma metabolite concentrations are given as geometric means (gMean) with their 
geometric SD (gSD), which has been suggested to better represent log-normally 
distributions, typical of biological measurements (234). The metabolite 
concentrations were log-transformed before analysis, and the between-group 
differences were assessed by one-way analysis of variance with planned contrasts 
performed for the two PPAR agonist groups versus the control group. Effect 
estimates were given as SMD (95% CI), and shown visually. The proportion of the 
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between-group variance explained by the models were evaluated by calculating the 
η2, and we adopted Cohen’s cutoff to define a large proportion of the variance 
explained at η2 > 0.35 (235). As the animals were taken out of the cages to receive 
treatment, we regarded the individual animal the experimental unit. 
3.2.3 Paper III 
Study design 
Paper III is a cross-sectional analysis based on the Western Norway B-vitamin 
Intervention Trial (WENBIT), consisting of 3090 participants initially randomized to 
receive tHcy-lowering B-vitamins. The source population for the trial was patients 
referred to coronary angiography for suspected coronary artery disease (CAD). Only 
patients diagnosed with stable angina pectoris (SAP) was included (n = 2573). The 
patients answered a food frequency questionnaire (FFQ) at baseline (Appendix I). 
Patients not completing the FFQ (n = 485) or leaving more than one page empty (n = 
80), as well as those reporting very high (>15,000 kJ/day for women and >17,500 
kJ/day for men) or low (<3000 kJ/day for women and <3300 kJ/day for men) total 
energy intake (n = 27) were excluded. Additionally, we excluded 52 patients who 
reported > 10 % of the total energy intake from alcohol, and one participant missed 
data on all outcome metabolites. After exclusions, the final study population 
consisted of 1928 participants, and Figure 3 provides a flow chart illustrating the 
selection process. 
The study protocol was in accordance with principles of the Declaration of 
Helsinki, and the study was approved by the Regional Committee for Medical 
Research Ethics, the Norwegian Medicines Agency, and the Data Inspectorate. The 
trial is registered at www.clinicaltrials.gov, with the identifier NCT00354081. 
Statistical analyses and presentation of results 
Baseline characteristics and plasma concentration of metabolites were represented by 
gMean (95% prediction interval [PI]) for continuous variables, and counts (%) for 
categorical variables, respectively. We chose to indicate the distribution by 95% PI 
instead of gSD for interpretability reasons. The 95% PI provides the limits of the 
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interval defined by (gMean/gSD2, gMean×gSD2). Dietary variables were adjusted 
using the density method (236) and expressed as energy percentage (E%) for 
nutrients contributing to total energy intake or as g/1000 kcal for food groups. 
 
Figure 3. Flowchart illustrating the selection of patients from the WENBIT source 
population for inclusion in paper III. FFQ indicate food frequency questionnaire; SAP, 
stable angina pectoris; WENBIT, Western Norway B-vitamin Intervention Trial 
 
Partial correlation was used to assess associations between dietary composition of 
macronutrients and intake of food groups, and linear regression was used to assess 
associations between intake of macronutrients and plasma concentrations of outcome 
biomarkers. We assessed these associations in a simple model adjusted for reported 
energy intake (Model 1), and in an additionoal model further adjusted for age, sex, 
BMI, smoking and alcohol intake (Model 2). Metabolite concentrations were log-
transformed before analysis, and by back-transforming the β-estimates the 
associations were expressed as % change in the outcome metabolite for an 
isoenergetic increment of 1 E% in the exposure nutrient (237). To evaluate the 
associations on the continuous scale, we fitted locally estimated scatterplot smoothing 
(LOESS)-curves adjusted for model 2 covariates. To visualize the uncertainty, we 
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generated hypothetical outcome plots where we plotted LOESS-curves based on 25 
bootstrapped samples of the data, methods provided by the R-package ungeviz (238). 
These plots represent hypothetical associations compatible with the data, and hence 
demonstrate the uncertainty in the observed associations. 
When the relative intake of one macronutrient increases, the relative intake of 
another must necessarily decrease. Both are of interest, as the net effect of increasing 
the intake of one nutrient could differ depending on what is replaced. Substitution 
analyses are increasingly utilized to mimic feeding studies of such dietary 
substitutions, especially when studying the substitution between energy-yielding 
macronutrients (239). In Paper III we mimicked all the specific dietary substitutions 
between the macronutrients by carrying out substitution analyses where all 
macronutrients except the one being replaced were included as covariates. 
Accordingly, the estimates indicated % change in the outcome metabolite per 1 E% 
increment in the exposure nutrient replacing the nutrient not included in the model. 
For example, we modeled the effect of protein replacing carbohydrates in a model 
where protein was the independent variable, and fat, alcohol and total energy intake 
were included as covariates. Theoretically, when fat, alcohol and total energy intake 
are fixed, any increase in protein intake must be accompanied by an isoenergetic 
decrease in carbohydrate intake. To evaluate the role of fat composition, we 
performed substitution analyses for the isoenergetic substitution between SFA, 
MUFA and PUFA. 
3.3 Statistical software 
The statistical analyses in Paper I was performed with IBM SPSS Statistics for 
Windows, version 21 (240). In Paper II and III, statistical analysis were performed 
with R (241), and the following packages within the tidyverse (242); broom (243), 
tidyr (244), dplyr (245), forcats (246), ggplot2 (247), haven (248), magrittr (249), 
purrr (250), rlang (251) and stringr (252), as well as effsize (253), forestplot (254), 
naniar (255), visdat (256), ungeviz (238), flextable (257), officer (258) and 
rmarkdown (259). 
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4. Summary of main results 
4.1 Paper I 
In Paper I, we wanted to explore the effect of pan-PPAR-agonist TTA on plasma and 
urine concentration of one-carbon metabolites. 
The most pronounced between-group differences observed (SMD [95% CI]) 
were higher plasma concentrations of NAM (6.1 [3.9, 8.2]), mNAM (4.3 [2.2, 6.5]), 
DMG (4.0 [2.4, 5.5]), MMA (3.8 [2.0, 5.5]) and PL (3.4 [2.0, 4.8]) in TTA-treated 
rats compared to the control group. Smaller differences were observed regarding 
urinary excretion of metabolites, but the large increase in plasma DMG and MMA 
was followed by their increased urinary excretion (SMD 1.7 [0.6, 2.8] and 2.1 [0.8, 
3.2], respectively). 
4.2 Paper II 
In Paper II, the main goal was to pursue and extend the observations from Paper I, 
by investigating the effects of specific activation of PPARα or γ. Further, we wanted 
to see whether the same observations would appear under different conditions. 
Figure 4 shows the gene expression of the PPARs and the two PPARα target genes 
LPL and ACOX1 in the intervention groups relative to control. PPARα expression 
was stronger in the liver in both intervention groups. The hepatic expression of LPL 
and ACOX1 was markedly increased after treatment with PPARα-agonist. Altogether, 
these findings confirmed activation of PPARα. 
Many metabolites differed between the groups, and in general the model 
explained a high proportion of the variance. PPARα-activation was associated with a 
number of metabolites, as well as larger differences from the control group compared 
to PPARγ-activation. The strongest differences observed between the PPARα group 
and control were increased NAM (SMD [95% CI] 6.6 [3.6, 9.5], η2 = 91 %), mNAM 
(5.9 [3.2, 8.6], η2 = 90 %), glycine (4.3 [2.2, 6.5], η2 = 81 %), DMG (3.4 [1.1, 5.3], η2 
= 68 %), PL (3.9 [1.9, 5.9], η2 = 74 %) and MMA (3.0 [1.3, 4.7], η2 = 73 %). 
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Figure 4. Liver and adipose tissue gene expression of PPARα, PPARγ, and the 
PPARα target genes LPL and ACOX1 in the PPAR-agonist groups relative to the 
control group represented by the dotted line. ACOX1, Acyl-CoA Oxidase 1; LPL, 
lipoprotein lipase. 
4.3 Paper III 
In Paper III, we set out to explore the associations between dietary composition and 
the one-carbon metabolome. As diet is known to influence PPARα-activity, we also 
wanted to compare the observations towards the two animal studies. 
Key baseline characteristics of the patient cohort are provided in Table 3. gMean 
(95% PI) age was 61 (44, 85) years, body mass index 26 (20, 34) kg/m2, and 1532 
(79.5 %) received lipid lowering statin treatment. 
When considering carbohydrate, protein and fat individually, the strongest 
associations towards the plasma one-carbon metabolites and markers of B-vitamin 
status were seen for increasing protein intake. For an isoenergetic increment of 1 E% 
from protein, we observed higher PLP (% change [95% CI], 3.1 [2.1, 4.1]), 
cobalamin (2.9 [2.1, 3.7]), riboflavin (2.4 [1.1, 3.7]), PA (2.2 [1.3, 3.2]) and mNAM 
(2.1 [1.1, 3.1]), and lower tHcy (-1.4 [-1.9, -0.9]) and MMA (-1.4 [-2.0, -0.8]). The 
substitution analyses indicated that it did not make a big difference whether protein 
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replaced carbohydrate or fat, suggesting that increased protein intake was the main 
determining factor. Increasing carbohydrate or fat intake was not strongly associated 
with plasma concentration of any outcome metabolite. The substitution analyses 
modeling changes in dietary fatty acid composition demonstrated that replacing SFA 
with MUFA or PUFA was associated with higher circulating mNAM, PL, PLP and 
folate, and lower plasma riboflavin, MMA and tHcy. 
Table 3. Baseline characteristics of patients included in paper III. 
 
  Total population Female Male 
n 1928 390 1538 
Male 1538 (79.8 %)   
Age, y 61 (43.9, 84.8) 63.2 (45.2, 88.4) 60.4 (43.7, 83.7) 
Waist Circumference, cm 96 (76, 121) 88 (67, 117) 98 (80, 119) 
BMI (kg/m2) 26.1 (19.8, 34.4) 25.8 (18, 37) 26.2 (20.3, 33.7) 
Smoking1 559 (29.0 %) 109 (27.9 %) 450 (29.3 %) 
HbA1c 5.82 (3.76, 9.02) 5.86 (3.8, 9.04) 5.82 (3.75, 9.01) 
Diabetes2 592 (30.7 %) 117 (30.0 %) 475 (30.9 %) 
Hypertension 911 (47.3 %) 200 (51.3 %) 711 (46.2 %) 
Previous AMI 835 (43.3 %) 145 (37.2 %) 690 (44.9 %) 
Statin use 1532 (79.5 %) 310 (79.5 %) 1222 (79.5 %) 
Variables are given as geometric mean (95% prediction interval) or as counts (%). AMI, acute 
myocardial infarction; BMI, body mass index; HbA1c, glycated haemoglobin. 
1Smoking is calculated from self-report, or plasma cotinine > 85 nmol/L 
2Diabetes is defined according to preexisting diagnosis, HbA1c > 6.5% or a blood glucose 
measurement > 7 mmol/L (fasting) or > 11.1 mmol/L (nonfasting) 
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5. Methodological aspects 
Preface 
This thesis includes data from studies carried out in rats and humans, where different 
exposures and conditions were investigated in relation to the same outcome variables. 
Methodological considerations pertaining to the different model systems are 
discussed separately in section 5.1 and 5.2, before joint considerations regarding 
outcome metabolites and statistical analyses are discussed in section 5.3 and 5.4. 
5.1 Animal studies 
Paper I and II were based on data derived from two studies in male Wistar rats, an 
outbred strain of Rattus norvegicus, which is an animal model frequently used in 
research (260). Some methodological considerations regarding these studies are 
merited, relating to the ethical aspects of animal research and the study design. 
5.1.1 The 3Rs and ethical considerations 
First developed in the 1950’s, the concept of the three R’s (3Rs; replacement, 
reduction, refinement) has become a fundamental part of the guidelines and 
legislation concerning the use of animals in research (261). Acknowledging that we 
will depend on the use of animal experiments in the foreseeable future, the 3Rs 
provide a basis for public acceptance of animal research by placing emphasis on 
causing a minimum amount of suffering to a minimum number of animals (262,263). 
The first R is replacement, and refers to all measures taken to avoid the use of 
animals. The replacement can be full, where the use of animals is avoided 
completely, or partial, where animals are replaced with other animals considered less 
capable or incapable of suffering, or with primary cells or tissues. The second R is 
reduction, and refers to all actions taken to reduce the number of animals used per 
experiment. This includes designing a study which maximize the amount of 
information collected from each animal, as it allows achieving the goal using less 
animals. The final R is refinement, which is related to all methods used to minimize 
pain and suffering to the animals. Factors like pain and stress are known to influence 
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the physiology of the animal. Hence, refinement contributes to better data quality, 
which again increases the potential for reduction. 
The principle of reduction is of relevance to this thesis, as both Paper I and II 
are based on available data from experiments originally investigating other outcomes. 
The data from Paper I was initially used to study the effect of TTA on gastric cancer 
(231), and the data from Paper II initially set out to explore short-term effects of 
PPAR-activation on lipid metabolism (233). By utilizing these data sets to estimate 
the effects of PPAR-activation on plasma concentration of one-carbon metabolites 
and B-vitamin status, we contribute to the literature suggesting a role of PPARα in 
the regulation of one-carbon metabolism, without sacrificing more animals. Data 
from animal experiments proves valuable also outside the scope of the initial 
outcomes of interest, and especially when exploring metabolic effects of specific 
interventions. Secondary use of animal data for targeted or untargeted metabolomics 
complies with the 3Rs and should be encouraged whenever possible, in order to 
colllect maximum information from each animal sacrificed. 
5.1.2 Cage effects and identification of the experimental unit 
The animals included in Paper I and II were not single-housed, meaning cage effects 
could be a potential source of bias. Cage effects refer to the situation where external 
factors influences one cage different from the other, introducing systematic 
differences between animals belonging to different cages. An example of such factors 
are vertical and horizontal cage placement in the racks. This may potentially cause 
different conditions with regard to light, temperature, noise etc. Another potential 
source of cage effects is when study procedures are performed cage by cage, on 
different days or time of day, or even by different personnel. To limit the influence of 
cage effects, randomization should apply to all aspects of the experiment, including 
cage placement and sequence of every experimental procedure and sacrifice. Single 
housing can eliminate cage effects, but is in general not recommended, as rats are 
social animals. The burden of being single housed could be a bigger concern than 
cage effects. 
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When analyzing data it is also important to identify the experimental unit of analysis: 
the smallest unit that can be allocated to different exposures. When all animals in a 
cage belong to the same experimental group, the cage would usually be considered 
the experimental unit. Treating each animal as independent observations may not be 
justified considering the potential for cage effects rendering the animals not truly 
independent. However, in some circumstances, using the individual animal as the 
experimental unit can be justified. This would be the case if the study treatment is 
given independent of the cages, and in a way in which it overrides the cage effect. In 
Paper II, animals of the same experimental group were housed in the same cages. 
However, on the basis that the animals were taken out of the cages to receive the 
study treatment, which was believed to affect the animals more profoundly compared 
to any potential cage effects, we decided to treat the individual animal as the 
experimental unit. We also performed sensitivity analyses where the cages were 
considered the experimental unit, which yielded similar results. 
Paper I was based on a subsample of a larger experiment, and at the time of 
analysis information regarding which animals belonged to the same cages, were not 
available. Hence, it was not possible to evaluate the potential for cage effects. We 
did, however, consider the individual rat as the experimental unit, although the 
potential for cage effects were high given that the treatment was given in the diet 
which was distributed per cage. Data on cage distribution has later been obtained 
from the original data, and Figure 5 illustrates a sensitivity analysis towards cage 
effects similar to what we did in Paper II. This suggests that although we treated the 
individual rat as the experimental unit, cage effects were not a big problem in Paper 
I. 
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Figure 5. Standardized mean differences 
(SMD) in plasma concentration of 
metabolites for between cages of rats 
receiving tetradecylthioacetic acid (TTA) 
treatment versus control. DMG, 
dimethylglycine; FMN, flavin mononucleotide; 
mNAM, methylnicotinamide; MMA, 
methylmalonic acid; PA, pyridoxic acid; PL, 
pyridoxal; PLP, pyridoxal-5-phosphate. 
 
5.1.3 Generalizing from rodents 
to humans 
The ultimate goal of health research is to 
provide useful information regarding 
human health, and ideally such knowledge 
should be generated in humans. However, 
for several reasons we are often not able 
to study a phenomenon in humans. 
Animals are used to unravel biochemical 
mechanisms, toxicity, as well as initial 
testing of drugs and novel therapies, 
which would be unethical or impractical 
to study in humans. Hence, we are still 
dependent on the use of animals, which has offered tremendous impact on human 
health and welfare (264,265). Single biological mechanisms may be explored in vitro, 
but although the 3Rs emphasize the need to replace animal research with cell culture 
experiments where possible, in vivo experiments are necessary to take into account 
the complex interactions between different organs going on within living organisms. 
Compared to human trials, the possibility of harvesting tissues in animal experiments 
facilitate a deeper investigation into physiological and mechanistic impact of diet and 
drugs. However, although humans and animals are astonishingly similar with regard 
to anatomy and physiology, some key between-species differences exists which 
complicates cross-species generalization. Hence, results from in-vitro and animal 
experiments should ultimately be tested and confirmed in human trials. Although 
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inbred animals are often more useful when studying specific metabolic mechanisms 
due to their genetic similarities, outbred strains better resembles the variance 
observed in humans, and the results may be of more relevance to the general human 
population. When comparing rodents and humans, one main difference of relevance 
to this thesis should be emphasized: rodents are a proliferating species, with more 
and stronger responses to PPARα-activation, as demonstrated in humanized mice 
models of PPARα-activation (197–201). This means that effects of PPARα-activation 
seen in rodents are not necessarily relevant for human physiology. However, some 
similarities have been demonstrated regarding the role of PPARα in the regulation of 
energy metabolism, especially in lipid metabolism (166), meaning some 
generalization is possible. 
5.2 Human study 
Paper III was a cross-sectional study linking self-reported dietary composition and 
baseline plasma concentration of outcome metabolites related to one-carbon 
metabolism and B-vitamin status. The observational nature of the study prevents 
causal conclusions, but as dietary exposure was recorded retrospectively, we may 
assume a temporal association between exposure and outcome. Accordingly, this 
study should be regarded as exploratory, and the results should be used to generate 
hypotheses that may be tested in other cohorts or experimental studies. Some main 
methodological limitations pertaining to paper III merits further consideration, 
primarily the potential sources of confounding and bias, the inherent limitations in 
self-reported dietary exposure data, and model building strategies. 
5.2.1 Confounding and bias 
Observed associations in epidemiological studies may or may not reflect a true 
exposure-outcome association. Considering the possibility of other explanations, such 
as confounding or bias, is paramount when attempting to untangle potential causal 
relationships. Confounding distorts the association, and bias refer to all factors 
leading to a systematic deviation between the observed and the truth. In observational 
research, many different sources of bias have been identified, broadly categorized 
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into information bias and selection bias. Confounding and bias threatens the internal 
validity, the extent to which a study measures what it is supposed to measure, within 
the context of data collection. 
Confounding 
A confounder is a factor associated with both the exposure and the outcome, but is 
not on the causal path between them. In randomized controlled trials, the purpose of 
randomization is equal distribution of factors other than the exposure of interest. 
Hence, differences between groups can be attributed to the exposure. Due to lack of 
randomization, observational research is prone to confounding, and indeed there are 
many examples of experiments failing to reproduce observational findings (266). 
Confounding cannot be mitigated by increasing the sample size, and must be handled 
otherwise, e.g. through stratification or adjustment. In Paper III, potential 
confounders would be factors associated with both dietary choices and the outcome 
metabolites, and the selection of covariates is discussed in more detail below. 
Two important concepts when handling confounding are especially relevant, 
namely residual confounding and unmeasured confounding, both of which are 
present in epidemiological studies (267). Residual confounding is due to 
nondifferential measurement error in a confounder, attenuating the confounder-
outcome relation. The effect on the exposure-outcome association is unpredictable, 
and depends on the direction of bias (267,268). Statistical adjustment is not able to 
fully remove the confounding when confounders are measured imprecisely (269), and 
one should be cautious in claiming independence based on persisting association after 
statistical adjustment (269,270). However, adjusting may still be better than not 
adjusting, as some confounding is removed. Unmeasured confounding refers to all 
the potential confounders not included in the model, of which the analyses cannot be 
conditioned upon. In the recent years an assumptionless measure of sensitivity toward 
unmeasured confounding has emerged (271,272), but unfortunately no 
straightforward way exists for its application in linear regression analyses. 
Considering dietary exposures, confounding due to healthy/unhealthy 
consumer bias is of special relevance, as intake of food is closely related to other 
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health-related variables, such as physical activity and smoking (266). Socioeconomic 
status is also closely related to diet quality (273). Self-selection of dietary and other 
health related exposures yield a high chance of bias due to confounding. A limitation 
in Paper III is our inability to account for healthy-consumer bias and socioeconomic 
status, which may be related to the inclination to follow official dietary guidelines 
and thus dietary composition. 
Selection bias 
Selection bias is related to the inclusion of participants, and is concerning the 
representativeness towards the source population. All studies are by definition 
conditioned on the hidden factor of being included or not, and systematic differences 
between the two may bias the estimates and limit external validity. The source 
population for Paper III was patients in Western-Norway, referred to coronary 
angiography for suspected CAD and diagnosed with SAP. Of the referred patients, 
3090 were originally randomized in the WENBIT trial. Characteristics of this cohort 
were comparable to other cohorts of patients with verified CAD (274). As SAP is not 
necessarily verified by angiography, it can be argued that compared to the general 
SAP population, our source population has more severe disease. On the other hand, 
willingness to participate in a trial may reflect personal traits such as health-
consciousness. This is a potential source of selection/nonresponse bias known as the 
healthy volunteer effect (275). 
There may be systematic differences between those willing to complete an 
FFQ and those who are not, which may be a concern for the study population in 
Paper III. This may relate to the FFQ being cognitively challenging and exhausting, 
potentially excluding the most severely ill patients. This may be further exacerbated 
by the healthy volunteer effect where health-conscious individuals are more likely to 
comply with the study protocol. Out of the 2573 eligible patients, 2088 (81 %) 
completed the FFQ. This was comparable to the FFQ completion rate in the full 
WENBIT cohort (80 %) (276), indicating that SAP-patients did not differ from non-
SAP-patients in their willingness to complete the FFQ. Further, we decided to 
exclude participants who left at least one blank page, or reported very high or low 
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intakes, and those reporting a high alcohol intake. The topic of excluding implausible 
reporters has been given some attention, and many methods exist (277–279). Using 
simple cutoffs, such as the ones used in Paper3, was shown to yield similar results as 
more sophisticated methods based on estimating energy requirements (278). 
Table 4 provides a numerical comparison of some key characteristics between 
participants included and those not included from the 2573 eligible patients. 
Compared to excluded individuals, participants were less likely to smoke, being 
diagnosed with diabetes or having experienced a previous AMI, and their CAD was 
somewhat less severe. Taken together, healthy volunteer effects and the inclusion 
process in Paper III may have introduced some selection bias. 
Table 4. Comparison of health-related characteristics between included and excluded 
participants in Paper III 
  Included Not included 
Age, y 61 (43.9, 84.8) 61.1 (43, 86.8) 
Male 1538 (79.8 %) 512 (79.4 %) 
Fasting 671 (34.8 %) 264 (40.9 %) 
BMI, kg/m2 26.1 (19.8, 34.4) 26.3 (19.7, 35.2) 
Waist Circumference, cm 95.7 (75.9, 120.8) 97 (77.2, 122) 
Smoking1 559 (29.0 %) 264 (40.9 %) 
Diabetes2 592 (30.7 %) 237 (36.7 %) 
Hypertension 911 (47.3 %) 304 (47.1 %) 
eGFR, ml/min/1.73m2 88.1 (59, 131.5) 88.8 (57.9, 136.3) 
Previous AMI 835 (43.3 %) 308 (47.8 %) 
Statin use 1532 (79.5 %) 497 (77.1 %) 
No significant stenosis 218 (11.3 %) 64 (9.9 %) 
1 vessel disease 543 (28.2 %) 187 (29.0 %) 
2 vessel disease 532 (27.6 %) 155 (24.0 %) 
3 vessel disease 635 (32.9 %) 239 (37.1 %) 
Variables are given as geometric mean (95% prediction interval) or as counts (%). AMI, 
acute myocardial infarction; BMI, body mass index; HbA1c, glycated haemoglobin. 
1Smoking is calculated from self-report, or plasma cotinine > 85 nmol/L 
2Diabetes is defined according to preexisting diagnosis, HbA1c > 6.5% or a blood glucose 
measurement > 7 mmol/L (fasting) or > 11.1 mmol/L (nonfasting) 
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Information bias 
Information bias refers to all factors influencing data collection, leading to 
misclassification of participants. Proper measurement of outcomes and covariates are 
important to maximize internal validity. However, most biological and physiological 
variables vary over time, following different patterns. Thus, measurement at a single 
time point does not necessarily reflect long-term exposure. Extreme values are 
typically followed by less extreme values on the next occasion, a statistical concept 
known as regression to the mean (275). This variation is a source of random 
measurement error, yielding regression dilution bias. Depending on the variable 
affected, this may cause attenuation (bias towards the null) or residual confounding, 
due to reduced influence of the variable in the model (268). This is a widely 
recognized effect of nondifferential measurement error, which most often holds in 
large samples (280), and we may thus assume that this is the case in Paper III. 
The main concern regarding information bias in Paper III pertains to the 
collection of self-reported dietary intake data. In nutritional epidemiology, we are 
mainly concerned with the long-term dietary exposure. As this is not directly 
observable, we depend on estimates derived from self-reported data. Dietary 
assessment in Paper III was done using an FFQ designed to capture the habitual 
Norwegian diet (281,282). As the FFQ presents the participants with the complex 
cognitive task of averaging their own intake, this is a common source of information 
bias, including systematic misreporting due to social desirability or recall bias. The 
inherent imprecision in dietary data has been the basis of a heated debate regarding 
the validity and usefulness of such data. Some go as far as claiming self-reported 
dietary data holds almost no value (283–286), while others emphasize that the data is 
valuable when handled correctly (287,288). The next section offers some perspectives 
on the perceived limitations of self-reported dietary data. 
5.2.2 Perspectives on dietary data 
Error structure in dietary instruments 
Several methods exist for dietary assessment, with different strengths and limitations. 
Common instruments include food records, 24h recalls and FFQs, which are 
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variously affected by measurement error. Food records and 24h recalls are heavily 
influenced by day-to-day and seasonal variation, which are considered sources of 
random measurement error when estimating long-run intake (290). In comparison, 
FFQs are more influenced by systematic errors related to misreporting, (291). 
However, although day-to-day variation have less influence, random and person-
specific errors still prevail (290,291). While random error can be mitigated by 
repeated measures, systematic errors will cause a persistent shift in the intake 
distribution. Intake-related measurement error such as under- or overreporting will 
also cause minor changes in the shape of the distribution. Random error mainly 
increases the variation (292). Based on simulated data, Figure 6 illustrates the 
expected effects of measurement error on the intake distribution as well as the 
association with an outcome metabolite, assuming a normally distributed true intake. 
 
Figure 6. Simulated data, demonstrating the expected effect of measurement error on 
the observed intake distribution and the association between dietary intake and an 
outcome. Grey color represents true intake distribution and association between intake and 
the outcome, red color represents the observed intake distribution and association with the 
outcome when different types of error are added to the intake variable. 
The different types of measurement error never appear in isolation, but in 
combination, meaning the data is still prone to bias (290,291,293). Based on the error 
structure, and the expected effect of the different measurement errors, it is clear that 
FFQs are not a suitable method to describe intake distributions in a population. 
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However, its ability to rank individuals according to their intake level make it suitable 
to assess diet-outcome associations. Hence, FFQ-derived dietary data may be 
considered suitable for the estimation of associations between dietary composition 
and biomarker concentrations in paper III. 
Dealing with measurement error in dietary data 
It is important to note that measurement error in cohort studies is most likely 
nondifferential, meaning it does not differ systematically according to the outcome. 
Accordingly, the main concerns regarding self-reported dietary data has traditionally 
been related to attenuation of associations and loss of statistical power, both related to 
regression dilution bias (294). Through validation studies, the amount of expected 
attenuation can be quantified, by evaluating how well the reported intake resembles 
true intake. Ideally, validation should be performed toward an unbiased estimate of 
the true intake, which unfortunately exists only for a few nutrients. The alternative is 
relative validation towards an instrument with less bias, such as repeated 24h recalls 
or food records. A potential pitfall when relying on relative validation is that the 
agreement between the methods are inflated due to correlated errors, overestimating 
the validity of the instrument. 
Some mitigation strategies exist to combat the measurement error in self-
reported dietary intake data. Energy adjustment takes advantage of the fact that the 
reporting errors in different foods, and nutrients, are highly correlated with reported 
total energy intake. There are several reasons to adjust reported intakes for total 
energy. First, expressing dietary intake relative to reported energy intake gives better 
estimates of the true intake (290,291,293,294). Second, total energy intake is closely 
related to factors such as body weight and physical activity level, and hence it is 
associated with several health outcomes. If total energy is associated with the 
outcome, so will all the nutrients making up the total intake, making total energy 
intake a confounder (236). Third, energy adjustment reduces the attenuation and 
increases precision in estimated associations (290,291,293–295). Fourth, by including 
energy intake, we estimate the effect of increasing the intake of one nutrient while 
simultaneously decreasing the intake of another. Such substitution effects are 
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ubiquitous in nutrition, also reflected in dietary guidelines. With some exceptions, 
dietary guidelines are based on substitutions, such as replacing some SFA with PUFA 
(296). Hence, when estimating diet-outcome associations, the adjusted risk estimates 
may often be more relevant, as they refer to changes in dietary composition. 
In Paper III we decided to use the density method, and express macronutrient 
intakes as E% and foods as g/1000 kcal. Using E% has the added benefit of being a 
well-established concept which is easy to relate to. By pooling the results from five 
validation studies of FFQ and 24h recalls, it was demonstrated that associations based 
on absolute protein intake was heavily attenuated, but less so when using protein 
density (expressing protein as E%) (291). The FFQ used in Paper III has previously 
been validated for energy intake and some macronutrients, demonstrating fairly good 
ability to rank participants according to macronutrient intakes when expressed as E% 
(297,298). Unfortunately, it was not possible to perform an internal validation in our 
cohort, which should be regarded a limitation. However, our decision to convert 
dietary intake to densities was justified in the literature and by previous validations 
studies. 
5.2.3 Model building strategies 
Selection of covariates for inclusion in the statistical model is an everlasting 
challenge, and no strict guidelines exists (299). One strategy is purposeful selection, 
where potential covariates are kept in the model if they satisfy a pre-specified 
criterion, which may be related to its influence on the exposure-outcome estimate 
(epidemiological criterion), or whether the variable is statistically significant in the 
model (statistical criterion). However, as this approach is data driven, and runs the 
risk of overfitting, it is regarded to be more appropriate in settings where prediction - 
and not causal inference - is the primary objective (299). Others have noted that this 
approach also runs the risk of ignoring true confounders (267,300). 
Another strategy has grown as part of the “new causality movement” in 
epidemiology (301). Here we take advantage of prior knowledge on the causal 
relationships between variables to identify parameters which are likely confounding 
the exposure-outcome association. This may be graphically represented by drawing 
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directed acyclic graphs (DAG) (300). Within this framework, one should carefully 
select covariates based on whether they are thought to confound the association you 
want to estimate, and avoid unnecessary adjustments potentially causing 
overadjustment bias (302). In Paper III, this approach was used for model building, 
and a simplified DAG is shown in Figure 7, where the variables in red was identified 
as relevant confounding variables. When modeling the associations to many different 
outcomes, a variable may be a confounder for one outcome, and not for another, 
which is a limitation. However, for simplicity and comparability reasons, we decided 
to apply the same model to all outcome metabolites. 
 
 
Figure 7. Simplified directed 
Acyclic Graph (DAG) for the model 
building process in Paper III. The 
red variables were identified as 
confounders for the association 
between the exposure nutrient and 
the outcome biomarker, and included 
in the model. BMI, body mass index. 
 
Two clear predictors of many plasma biomarkers are kidney function and fasting 
status. The case could be made to include these variables in the linear regression 
models for the purpose of increasing precision (302). However, these parameters 
were assumed not to be related to the exposure, and thus not considered confounders. 
In the name of parsimony, we therefore opted to not include them in the final model. 
The same decision was made for inflammation and medication use such as statins. As 
recommended, we additionally adjusted the model for reported energy intake (287). 
For interpretation reasons we also decided to include reported alcohol intake in the 
model, as we wanted to estimate the effect of increasing the intake of one 
macronutrient at the expense of another, not at the expense of alcohol. 
Another issue is related to categorization of continuous variables, typically 
leading to misclassification (303), and adjustment for categorical variables removes 
less confounding (299). Although inherently continuous, smoking exposure was 
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dichotomized into smokers and non-smokers, based on self-report and plasma 
cotinine. Taking advantage of cotinine, a biomarker of nicotine exposure, reduces the 
risk of smoker misclassification. However, lack of data on smoking intensity is a 
potential source of residual confounding (303). 
5.2.4 Generalizability 
The first prerequisite for generalizability is internal validity. Good internal validity 
does, however, not guarantee external validity. The source population in Paper III 
has been reported to be fairly representative for the general CAD population, and 
although some selection bias is likely, the results should be at least partly 
generalizable. However, the cohort mostly consisted of middle-aged to elderly 
Caucasian men, of which most were treated with lipid-lowering medications. Hence, 
it can be argued that extrapolation of our findings to healthy populations with other 
age, gender or ethnical compositions should be done with caution. 
5.3 Collection of outcome metabolites and covariates 
The outcome metabolites for all three papers included in this thesis were quantified at 
a single time point from blood samples, and some methodological considerations 
need addressing. First, nutritional biomarkers are often influenced by fasting status. 
In Paper I, the animals were sacrificed in the non-fasting state, while the animals in 
Paper II were fasted. Given the focus on PPARα, which is induced in the fasting 
state (179,180), this could be a source of variation between the studies. However, the 
results of Paper I and II are largely consistent, suggesting that the pharmacological 
PPARα-activation overrides the potential effect of fasting. Imprecise measurements 
of the outcome metabolites may stem from analytical variation, and all the outcome 
variables in the current thesis were measured with some degree of uncertainty as 
indicated by the intraclass correlation coefficients reported in Table 1. However, 
when used as outcome variables, these measurement errors are not contributing to the 
regression dilution bias, as the regression analyses estimate the average response 
which is not influenced by random error. Hence, analytical sources of variation is not 
considered a major limitation in this project. 
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5.4 Statistical modeling and the garden of forking paths 
The three papers included in this thesis represents a journey through the garden of 
forking paths, a concept first described by statisticians Andrew Gelman and Eric 
Loken, related to the phenomenon of multiple comparisons. By forking paths, they 
refer to all the choices we make when building statistical models, also referred to as 
researcher degrees of freedom (304). They argue that when decisions are made 
contingent on the data, different data would lead to different choices; hence we would 
be testing a different model. 
5.4.1 Presentation of data 
Descriptive statistics provide a numerical summary of the data, most often by 
providing information on the central tendency and the variability/spread. Comparing 
descriptive statistics directly provide an informal way of between-group comparisons, 
and assess representativeness between populations such as the WENBIT population 
(274). Distributions are commonly characterized by a central tendency, typically the 
mean, and a measure of variance, typically the SD. The interval within ± 1 SD from 
the mean is expected to cover ~68% of the distribution, while ± 2 SD covers ~95%. 
These properties do not hold true for log-normal distributions, which are commonly 
encountered in biological measurements (234). As the data are skewed, the interval 
will commonly span too far below the central estimate, and not far enough above. As 
most observations lie below the mean, these intervals will contain a larger proportion 
of the values, and frequently also contain negative values. The corresponding 
intervals for log-normal distributions are (gMean/gSD, gMean×gSD) and 
(gMean/gSD2, gMean×gSD2), yielding an asymmetric interval surrounding the 
gMean containing ~68% and ~95% of such distributions. 
Figure 8 illustrates a log-normal distribution with geometric mean 100 and 
gSD 2. The red area represents the interval within the mean (128.2) ± one (28.8, 
227.6) or two (-70.7, 327.1) SD, containing 84.4 and 95.5 % of the distribution, 
respectively. However, this interval also contain negative values, which are 
biologically impossible. The grey area illustrates the geometric mean (100) and the 
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intervals contained within one (50, 200) or two (25, 400) gSD, containing 68.0 and 
95.4 % of the distribution. 
 
Figure 8. Illustration of a log- 
normal distribution and its 
descriptive statistics measured 
on different scales. The red 
area shows the interval contained 
within one or two standard 
deviations from the arithmetic 
mean, and the grey area shows 
the intervals covered within one 
or two geometric standard 
deviations from the geometric 
mean. 
 
In Paper I, we reported arithmetic means (SD), which in hindsight was a suboptimal 
choice, as exampled by some of the intervals within ± 2SD contained negative values 
for several metabolites. In Paper II and III, we followed the recommended approach 
by reporting the gMean (gSD). However, as gSD is a multiplicative measure of 
variation, it is not intuitively interpreted. Accordingly, we opted to calculate the 95% 
PI, corresponding to the grey area in Figure 8, when presenting data in Paper III. 
Although different choices were made regarding data transformation in Paper I and 
II, the standardized effect size facilitated between-study comparability, and in this 
case also easier comparison between the different metabolites present in very 
different concentrations. A later reanalysis (not shown) of Paper I, when metabolites 
were log-transformed before analysis, yielded very similar results. 
Categorization of continuous variables is common practice, and the main 
advantage is related to interpretability, as it facilitates comparison between 
categories. However, categorization invariably leads to loss of power due to reduced 
influence of the data range, Also, the (often inappropriate) assumption of 
homogeneity within groups almost never holds. A third disadvantage is that groups 
will be defined differently across studies, making cross-study comparison difficult 
(305). Analyses on the continuous scale are more powerful, but interpretation is 
harder. In Paper III, we kept the dietary exposure variables continuous, and reported 
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the point estimates per isoenergetic increment of 1 E%. However, in presence of non-
linearity, this approach by itself is not sufficient. Hence, the main results were shown 
graphically by plotting the continuous association between the exposure nutrient and 
the outcome metabolite concentration predicted by the model. This approach 
demonstrates potential non-linear associations without the drawbacks of 
categorization. The graphical approach also encourages a focus on the direction of 
effects as well as potential thresholds where an effect occurs, changes or ceases, 
which is highly relevant in terms of making broader, clinically relevant inferences. 
5.4.2 Multiple comparisons 
Multiple comparisons continue to be a hot topic for debate, and is of relevance for all 
papers included in this thesis. In Paper I, we adjusted the analyses for multiple 
comparisons by using the false discovery rate method of Benjamini and Hochberg 
(232). After careful consideration we opted not to perform any correction for 
multiplicity in Paper II and III, a decision made on the basis of arguments in the 
literature (306). Traditionally, the main concern when testing many associations is 
related to the inflated risk of falsely claiming an association. Methods of multiple 
comparison correction reduces the false positive rate, although on the expense of 
decreasing statistical power and inflating the risk of false negatives. Accordingly, it 
has been argued that corrections only make truly sense if studying random numbers, 
where all associations per definition are false positives (306). Further, Gelman and 
Loken stress the fact that multiple comparisons not only concern all the different 
comparisons that were made, but all the potential comparisons that could have been 
made, which in theory is endless (304). They emphasize that a single association may 
be analysed in a multitude of ways, with many researcher degrees of freedom. Paper 
I, II and III were all based on data where many comparisons have already been 
published, and many more comparisons were made within the current papers. For 
Paper III, we also have the issue of covariate selection, inflating the number of 
potential comparisons drastically. The final decision of not correcting for multiple 
comparisons in Paper II and III was made on the basis of the mainly explorative 
nature of these papers, and in hindsight it can be argued that the correction applied to 
Paper I was unnecessary. 
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5.4.3 Statistical significance and replication 
The cornerstone in statistical inference has for long been null-hypothesis significance 
testing, where an observation is deemed statistically significant or not based on its p-
value. This culture has received harsh criticism for contributing to publication bias, 
overestimation of effects and ultimately the current replication crisis (307). Formally, 
the p-value is a continuous measure of the compatibility between the observed data 
and a specified statistical model, commonly the null-hypothesis of no difference, 
given that all assumptions of the test holds (308). Due to many widespread 
misconceptions regarding p-values, the American Statistical Association issued a 
statement on statistical significance and p-values, emphasizing the many drawbacks 
of relying on p-values when making conclusions (309). One major pitfall of relying 
on declaration of statistical significance is that two studies may be largely consistent, 
yet be wrongly interpreted as being in conflict, when the decision is made based on 
the presence or absence of statistical significance (310–312). Arguably, least as 
important as not claiming something to be true or important when p < 0.05, is to 
avoid claiming “no effect” when p > 0.05, frequently referred to as “absence of 
evidence is not evidence of absence” (313). 
In 2019, another statement was issued (314), effectively calling to abandon the 
dichotomous practice of declaring a result statistically significant or not. This has 
been supported by others (300). Accordingly, in Paper II and III we did not 
determine a cutoff for statistical significance, and reported all results without 
dichotomization. This decision was based on the explorative nature of these studies, 
and the notion that formal statistical inferences is not valid for this purpose (315). 
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6 Discussion of results and future considerations 
The main aim of this thesis was to study the effects of PPARα-activation and dietary 
composition on the circulating one-carbon metabolome. Consistent findings from the 
animal studies included increased concentrations of NAM, mNAM, DMG, PL and 
MMA. In the human study, the strongest observed associations were related to 
protein intake, which was associated with increased PLP, PL, cobalamin, riboflavin 
and mNAM, as well as lower tHcy and MMA. Interestingly, estimated effects of 
changing fat composition suggested that replacing SFA with PUFA elicited similar 
alterations in metabolite concentrations as was observed with PPARα-activation in 
the animal studies, including higher mNAM and PL, and lower riboflavin. The main 
overall strength of the included studies in this thesis is the targeted metabolomic 
approach to characterize the effects on the one-carbon metabolome, using both 
animal and human data. 
6.1 Potential mechanisms 
6.1.1 The effect of pharmacological PPARα-activation 
In Paper I and II, we observed consistent patterns of higher plasma concentration of 
several outcome metabolites after PPARα-activation. An important finding is that 
these observations were consistent across the very different study durations, the 
context of different background diets as well as the fasting vs non-fasting blood 
samples. Collectively, this demonstrates that PPARα-activation has a sustained and 
more pronounced effects on the one-carbon metabolome compared to these other 
factors. 
The increased plasma concentrations of NAM and mNAM is likely due to 
increased tryptophan-to-NAD conversion in the liver, as PPARα-activation inhibits 
ACMSD and stimulates QAPRT (170,217,219,221,222). PPARα stimulates β-
oxidation of fatty acids, a process that depends on NAD+, and it is possible that a 
concomitant increase in NAD availability is an adaptation related to increased 
requirements (217). PPARα-activation is known to reduce inflammation, and 
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increased methylation of NAM to mNAM has been suggested to be an adaptive 
response to inflammation (111). Indeed, NNMT is not normally saturated, and 
increased NAM levels will subsequently lead to increased mNAM (316). This could 
also contribute to the higher tHcy levels seen with fibrate treatment (202). The 
regulation of NNMT has not been extensively studied (316), and whether it is a 
PPARα target gene is not known. However, NNMT expression is associated with 
effects on the circulating lipid profile similar to what is observed with PPARα-
activation (316). Interestingly, although not normally considered a major consumer of 
hepatic SAM, increased NAM methylation may reduce the flux through GNMT, 
which usually acts as a regulator of cellular methylation capacity. This may have 
contributed to the increased glycine concentrations observed. 
We observed a marked increase in PL in the treatment groups. However, PLP 
is normally the main circulating B6 form. ALP is the enzyme responsible for 
converting PLP to PL, and previous studies have reported increased expression of 
ALP after PPARα-activation (217,219,223,224). Vitamin B6 is known to be inversely 
associated with inflammation (70). Hence, consistent with the anti-inflammatory 
properties of PPARα, higher concentrations of vitamin B6 biomarkers may be related 
to lower inflammation. A potential partitioning towards PL may be due to increased 
conversion through ALP. Further, the conversion of the phosphorylated forms of 
pyridoxine and pyridoxamine to PLP depend on FMN, which was lower after 
PPARα-activation, potentially limiting PLP synthesis. 
Increased MMA was consistently observed after PPARα-activation, and may 
be related to increased production or reduced metabolism of methylmalonyl-CoA. 
Precursors of methylmalonyl-CoA includes odd-chain fatty acids and branch-chained 
amino acids, both of which encounter increased catabolism during PPARα-activation. 
However, increased MMA may also be related to PPARα-induced interference with 
cobalamin function. Indeed, a search in the PPARgene database (317) identified two 
key enzymes in the intracellular processing of cobalamin, MMACHC and MMADHC, 
as predicted PPARα target genes. Further, MMACHC is dependent on riboflavin and 
glutathione for its function (318,319). We observed lower riboflavin and FMN, and 
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could thus expect glutathione to be reduced due to inhibition of the transsulfuration 
pathway as well as the anti-oxidative properties of PPARα. 
In the choline oxidation pathway, the most pronounced effect was seen for 
increased DMG. The most evident explanation for this observation is related to 
reduced catabolism, as PPARα-activation downregulates both DMGDH and SARDH 
(170), resulting in lower protein levels (213,214). Reduced oxidative stress following 
PPARα-activation may facilitate BHMT flux (35), consistent with the observed 
increase in DMG. Further, PPARα downregulates both enzymes of the 
transsulfuration pathway (170,208), and the resulting increase in intracellular Hcy 
increases substrate availability for the Hcy remethylation enzymes. As serine 
condenses with Hcy to form cystathionine, reduced transsulfuration flux may also 
contribute to the increased concentrations of serine and glycine. 
6.1.2 The effect of dietary composition 
In Paper III, we observed several associations between dietary composition of 
macronutrients and the one-carbon metabolome, mainly with increasing protein 
intake. Of particular interest for this thesis, the modeled effects of substituting SFA 
with PUFA, which has been suggested to elicit stronger activation of PPARα, were 
similar to the effects seen with PPARα-activation in Paper I and II. 
The most obvious explanation for the associations seen with increasing protein 
intake is related to the food profile. Higher protein intake in this cohort was 
characterized by increased intakes of fish, meat, dairy and vegetables, and lower 
intakes of fruit, berries, grains and potatoes. Protein-rich food of animal origin are 
rich sources of vitamin B6, niacin, folate and cobalamin, which is consistent with the 
higher concentrations of these vitamins. Further, dairy is the main dietary source of 
riboflavin, which is in accordance with higher plasma riboflavin. An inverse 
association between protein intake and plasma tHcy is consistent with what has 
previously been reported (320). Based on the inverse association between tHcy and 
folate, vitamin B6 and cobalamin, lower tHcy would be expected with higher intake 
of these nutrients. Further, increased intake of methionine provides the precursor for 
SAM synthesis, which stimulates Hcy catabolism through the transsulfuration 
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pathway. Increased intracellular SAM may activate mechanisms to scavenge the 
excess methyl groups, such as GNMT. This may partially explain the inverse 
association between protein intake and plasma glycine. Additionally, increased 
methylation of NAM is another potential methyl sink (316), and is consistent with the 
higher concentrations of mNAM observed. The higher plasma concentrations of 
methionine and sarcosine, as well as lower tHcy and glycine, may thus be related to 
dietary influences on methylation status. The lower plasma MMA is consistent with 
increasing cobalamin intake following higher intakes of animal food. As the 
associations with increasing protein intake were consistent regardless of whether 
protein replaced carbohydrate or fat, this suggests that the associations are mainly 
driven by protein.When modeling the substitution between different fatty acid 
classes, replacing SFA with PUFA was related to higher mNAM, PLP, PL, PA, 
folate, as well as lower riboflavin, tHcy and MMA. Based on unsaturated fatty acids 
being more potent PPARα-activators, such change has previously been hypothesized 
to yield stronger PPARα-activation (168). There are similarities between some of 
these observations and what was observed with PPARα-activation in Paper I and II. 
Hence, we may speculate that diet-induced alterations in PPARα-activity may be 
involved. As we did not measure PPARα expression or activity in the current study, 
this must be explored in future studies. 
A direct comparison to the findings in Paper I and II is hampered by the 
much more complex situation faced in Paper III. Altering dietary composition 
changes many variables simultaneously, and other factors including physical activity, 
smoking, body weight and composition and nutritional status such as over- or 
undernutrition will unavoidably influence the metabolic phenotype. Further, although 
substitution analyses attempt to simulate feeding studies, they do not directly assess 
an actual dietary substitution. Thus, we speculate that dietary macronutrient 
composition, and fatty acid composition, may influence one-carbon metabolism 
partly through altering PPARα-activity. However, this is not necessarily directly 
mediated through binding of a PPARα-ligand. Activity of the PPARα/RXR-complex 
may also be influenced by binding of RXR-ligands (163). Further, RXR also 
heterodimerize with other nuclear receptors such as retinoic acid receptor, vitamin D 
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receptor, liver X receptor and thyroid hormone receptor. In total, it is estimated that 
RXR dimerize with a third of all human nuclear receptors, facilitating their function 
(163). Thus, altered PPARα-activity may depend on RXR availability, which depend 
on the requirement to dimerize with other nuclear receptors. Hence, dietary influence 
on PPARα-activity may be both direct by providing PPARα-agonists, and indirect 
through interfering with other RXR-dependent receptors. 
6.2 Clinical application and the way forward 
There are no direct clinical application of the findings in this project at the current 
time. However, the findings lays the foundation for future research into the regulation 
of one-carbon metabolism, with potential implications for treatment or personalized 
medicine and nutrition. The following sections provides a discussion on how the 
findings presented herein could form the basis for future research, aiming to further 
increase our knowledge of the intersection between one.carbon metabolism, PPARα 
and diet. 
6.2.1 Association, causation and the issue of adaptive mechanisms 
When the concentration of a biomarker is associated with the risk of a clinical 
endpoint, the biomarker may be considered a risk marker. However, this does not 
necessarily mean that the biomarker is causally linked to the disease. There is always 
a possibility that the metabolite concentration is changed as a response to other 
factors associated with the disease, and may even be part of an adaptive or protective 
mechanism. Hence, treatment aimed at “correcting” the levels of a biomarker for 
disease risk is not necessarily beneficial. Accumulation of firefighters in the 
proximity of a fire is a helpful analogy, where the firefighters can be seen as a marker 
associated with fire risk. Although high concentrations of the risk marker is 
associated with increased risk of the outcome, removing the risk marker when first 
present will obviously be a bad idea. This is of course a clear-cut example of reverse 
causality, but the same logic may be applied to biological biomarkers of disease risk. 
One example is inflammation, which is part of the physiological response to harmful 
stimuli. 
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When a metabolite is associated with the risk of an outcome, it is always 
important to consider the possibility that the metabolite is altered as a response to 
disease mechanisms. This is crucial when making a decision of whether to correct the 
metabolite level or not. If the metabolite concentration is altered as part of a 
protective mechanism, “correcting” the concentration may do more harm than good. 
Conversely, if the metabolite is mediating the effect of the primary cause on the 
outcome, or has negative health effects per se, treatment targeting the metabolite 
level may be appropriate. The challenge is identifying which is which, and when 
interpretation of adaptation vs causality is difficult, we should also be conservative in 
our decision to treat (321). Related to one-carbon metabolism, tHcy is a good 
example of a metabolite associated with increased disease risk, but where lowering 
concentrations have mostly failed to improve prognosis (85), suggesting that elevated 
tHcy is an adaptive marker of underlying pathology (86,87). This means that it is the 
cause of elevated tHcy, and not the tHcy per se which is problematic. 
6.2.2 A note on the future of nutritional epidemiology 
As argued by Beaton and others (287,322), it is absolute key to continue increasing 
our ability to handle the inevitable measurement errors in dietary self-reports. Thus, 
when planning future epidemiological studies, it is important to include mitigation 
strategies for measurement error, to improve estimation (323). Methods exist to 
correct this error, but may require additional data to be collected. The most 
widespread method of correcting for measurement error is regression calibration, a 
form of exposure modeling where predicted intakes replace reported intakes in the 
model (294). Predicted intakes are obtained from a calibration equation from reported 
intakes and relevant covariates. A prerequisite for this approach is the availability of 
more accurate data in a subset, to perform an internal validation study. As recovery 
biomarkers are sparse, the best alternative is to plan for the collection of repeated 24h 
recall interviews in addition to the FFQ. Collecting repeated 24h recalls in a subgroup 
allows for regression calibration (294), but if collected for the whole cohort, 
combining the instruments have proven superior (324). Another way of improving 
dietary intake data is combining self-reported data with biomarkers (325,326). To 
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facilitate valid inferences on diet-outcome associations in future studies, properly 
planning the collection of dietary data is of utmost importance. 
6.2.3 A note on extending the use of metabolomics 
Metabolomics refer to the comprehensive and quantitative analysis of all metabolites. 
A less global approach is targeted metabolomics, where the focus is on a smaller, 
more specific set of metabolites. All papers in the current thesis belongs to the field 
of targeted metabolomics (327). Modern laboratories, such as Bevital A/S, have 
developed methodology allowing simultaneous quantification of many metabolites 
from low volumes of biological fluids. Metabolomic analyses of epidemiological 
studies are a great starting point for exploring the metabolic profile in relation to 
different exposures, such as we did with dietary composition in Paper III. 
Metabolomic analyses of animal experiments may contribute to the unraveling of the 
complex regulation of different metabolic pathways, which was our focus in Paper I 
and II. However, the real strength lies in the use of metabolomics in clinical 
intervention studies, e.g. as we did using data from a randomized trial of changed 
dietary fat composition (148). The observed associations from the current thesis could 
be further explored by including the quantification of one-carbon metabolites in other 
observational and experimental studies of dietary exposure. 
6.2.4 A note on precision nutrition and the importance of subgroup 
analyses 
In studies, whether observational or experimental, we are mostly concerned with 
effects on the group level. This is fundamentally different from determining the best 
approach on the individual level (328). Many scenarios may lead to the same average 
effect in a population, including but not limited to large effects in small subgroups, 
and untangling them could potentially be of paramount importance to clinical 
practice. The existence of heterogeneity of individual responses is widely 
acknowledged, and the concept of precision nutrition has become a hot topic (329). 
To improve clinical decision making, the main crux is to identify those who will 
benefit from, or potentially be harmed by, a given recommendation or treatment. The 
first step in this process is the screening for putative indicators, and an accessible tool 
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is subgroup analyses to explore potentially diverging patterns within different 
subgroups. As subgroup analyses run a high risk of bias, their results have often been 
looked at with disdain (330). However, the importance of exploratory subgroup 
analyses have been emphasized (315), although results should always be regarded 
hypothesis generating and must be externally confirmed (331). 
Another possible tool is genetic analyses, successfully implemented in the 
treatment of inborn errors of metabolism. Genetic screenings for the purpose of 
personalized nutritional advice are already readily available commercially, but its 
validity has been questioned (332). Related to one-carbon metabolism, a genetic 
variant in MTHFR has been demonstrated to increase the risk of hypertension, which 
may be treated with riboflavin supplementation (333). 
Metabolic phenotyping represents another approach to personalized nutrition. 
In Paper I and II, we suggest several potential biomarkers of PPARα, including 
plasma concentration of mNAM, NAM, DMG, PL and MMA, which individually or 
combined may provide information on PPARα-activity. Given the crucial role of 
PPARα in the regulation of energy metabolism, information on its endogenous 
activation may provide clues when considering tailored nutritional advice. Indeed, 
some interactions between genetic PPARα-variants and diets have been reported 
(160), indicating that endogeneous PPARα activity may mediate inter-individual 
variations in response to dietary exposures. To extend the findings from Paper I and 
II to humans, targeted metabolomics should be applied to (existing) human trials of 
fibrate treatment. However, given the central question of causation vs adaptation, it 
remains to be unraveled if different dietary advice should be given to persons with 
high or low endoogenous PPARα-activity. A natural next step is therefore to explore 
the effect of different dietary exposures in cohort and intervention studies, using 
targeted metabolomic profiling to identify subgroups of interest. If consistent patterns 
emerge, the ultimate test would be to carry out a randomized trial of such advice with 
block randomization according to metabolic phenotype. 
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7. Conclusions 
The main finding of this thesis is that the one-carbon metabolome is influenced by 
both PPARα-activation and dietary composition. The effects of pharmacological 
PPARα-activation were consistent across different conditions, suggesting a profound 
role of PPARα in the regulation of one-carbon metabolism. The most striking 
findings were higher mNAM, NAM, PL, DMG, glycine and MMA, suggesting these 
metabolites as potential biomarkers of PPARα-activity. This also suggests links 
between lipid and one-carbon metabolism, which have not been investigated 
thoroughly so far.  
In humans, dietary composition was associated with the one-carbon 
metabolome, with the strongest associations observed for protein intake. Higher 
protein intake was associated with higher concentration of PLP, cobalamin, riboflavin 
and mNAM. The modeled effect of substituting SFA with PUFA in humans showed 
similarities with the metabolic profiles observed after PPARα-activation in the animal 
studies, especially regarding the concentrations of riboflavin, mNAM, PL, PLP and 
DMG. This suggests that dietary fatty acid composition influences one-carbon 
metabolism, potentially through interfering with PPARα-activity. 
Intervention studies in humans would be the next step to further our 
understanding regarding the role of PPARα and dietary composition in one-carbon 
metabolism. Similar to the studies conducted in this thesis, it would be beneficial to 
apply targeted metabolomics to existing studies with stored biological samples and 
well-characterized diets, instead of conducting new trials. These analyses may also 
provide information on individual variation in response to dietary exposure, and may 




1. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46.  
2. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, et al. S-
Adenosylmethionine and methylation. FASEB J. 1996;10(4):471–80.  
3. Cantoni GL, Scarano E. The Formation of S-Adenosylhomocysteine in 
Enzymatic Transmethylation Reactions. J Am Chem Soc. 1954;76(18):4744.  
4. De La Haba G, Cantoni GL. The enzymatic synthesis of S-adenosyl-L-
homocysteine from adenosine and homocysteine. J Biol Chem. 
1959;234(3):603–8.  
5. Brosnan JT, Jacobs RL, Stead LM, Brosnan ME. Methylation demand: a key 
determinant of homocysteine metabolism. Acta Biochim Pol. 2004;51(2):405–
13.  
6. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. 
Total homocysteine in plasma or serum: methods and clinical applications. Clin 
Chem. 1993;39(9):1764–79.  
7. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocystine in the 
urine. Biochem Biophys Res Commun. 1962;9:493–6.  
8. Hatch FT, Larrabee AR, Cathou RE, Buchanan JM. Enzymatic synthesis of the 
methyl group of methionine. I. Identification of the enzymes and cofactors 
involved in the system isolated from Escherichia coli. J Biol Chem. 
1961;236:1095–101.  
9. Larrabee AR, Cathou RE, Buchanan JM, Rosenthal S. Enzymatic Synthesis of 
Methyl Group of Methionine .4. Isolation, Characterization, and Role of 5-
Methyl Tetrahydrofolate. J Biol Chem. 1963;238(3):1025 –&.  
10. Loughlin RE, Elford HL, Buchanan JM. Enzymatic Synthesis of the Methyl 
Group of Methionine. Vii. Isolation of a Cobalamin-Containing Transmethylase 
(5-Methyltetrahydro-Folate-Homocysteine) from Mammalian Liver. J Biol 
Chem. 1964;239.  
11. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. 
Human methionine synthase: cDNA cloning and identification of mutations in 
 77
patients of the cblG complementation group of folate/cobalamin disorders. Hum 
Mol Genet. 1996;5(12):1867–74.  
12. Borsook H, Dubnoff JW. Methionine Formation by Transmethylation Invitro. J 
Biol Chem. 1947;169(2):247–58.  
13. Finkelstein JD, Harris BJ, Kyle WE. Methionine metabolism in mammals: 
kinetic study of betaine-homocysteine methyltransferase. Arch Biochem 
Biophys. 1972;153(1):320–4.  
14. Pajares MA, Perez-Sala D. Betaine homocysteine S-methyltransferase: just a 
regulator of homocysteine metabolism? Cell Mol Life Sci. 2006;63(23):2792–
803.  
15. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, et al. Cloning 
and mapping of a cDNA for methionine synthase reductase, a flavoprotein 
defective in patients with homocystinuria. Proc Natl Acad Sci U S A. 
1998;95(6):3059–64.  
16. Olteanu H, Banerjee R. Human methionine synthase reductase, a soluble P-450 
reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine 
synthase activation. J Biol Chem. 2001;276(38):35558–63.  
17. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of 
homocysteine between competing pathways. J Biol Chem. 1984;259(15):9013–
508.  
18. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419–
9.  
19. Rosado JO, Salvador M, Bonatto D. Importance of the trans-sulfuration 
pathway in cancer prevention and promotion. Mol Cell Biochem. 2007;301(1-
2):1–12.  
20. Binkley F. Synthesis of cystathionine by preparations from rat liver. The Journal 
of biological chemistry. 1951;191(2):531–4.  
21. Selim AS, Greenberg DM. An enzyme that synthesizes cystathionine and 
deaminates L-serine. J Biol Chem. 1959;234(6):1474–80.  
 78
22. Kashiwamata S, Greenberg DM. Studies on Cystathionine Synthase of Rat 
Liver Properties of Highly Purified Enzyme. Biochim Biophys Acta. 
1970;212(3):488 –&.  
23. Carroll WR, Stacy GW, Duvigneaud V. Alpha-Ketobutyric Acid as a Product in 
the Enzymatic Cleavage of Cystathionine. J Biol Chem. 1949;180(1):375–82.  
24. Matsuo Y, Greenberg DM. A crystalline enzyme that cleaves homoserine and 
cystathionine. I. Isolation procedure and some physicochemical properties. J 
Biol Chem. 1958;230(2):545–60.  
25. Williams KT, Schalinske KL. New insights into the regulation of methyl group 
and homocysteine metabolism. J Nutr. 2007;137(2):311–4.  
26. Kerr SJ. Competing methyltransferase systems. J Biol Chem. 
1972;247(13):4248–52.  
27. Luka Z, Mudd SH, Wagner C. Glycine N-methyltransferase and regulation of S-
adenosylmethionine levels. J Biol Chem. 2009;284(34):22507–11.  
28. Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A Metabolic Function for 
Phospholipid and Histone Methylation. Mol cell. 2017;66(2):180–193.e8.  
29. Goulding CW, Matthews RG. Cobalamin-dependent methionine synthase from 
Escherichia coli: Involvement of zinc in homocysteine activation. Biochemistry. 
1997;36(50):15749–57.  
30. Millian NS, Garrow TA. Human betaine-homocysteine methyltransferase is a 
zinc metalloenzyme. Arch Biochem Biophys. 1998;356(1):93–8.  
31. Taoka S, Ohja S, Shan X, Kruger WD, Banerjee R. Evidence for heme-
mediated redox regulation of human cystathionine beta-synthase activity. J Biol 
Chem. 1998;273(39):25179–84.  
32. Janosik M, Kery V, Gaustadnes M, Maclean KN, Kraus JP. Regulation of 
human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for 
two catalytically active conformations involving an autoinhibitory domain in the 
C-terminal region. Biochemistry. 2001;40(35):10625–33.  
33. Mosharov E, Cranford MR, Banerjee R. The quantitatively important 
relationship between homocysteine metabolism and glutathione synthesis by the 
 79
transsulfuration pathway and its regulation by redox changes. Biochemistry. 
2000;39(42):13005–11.  
34. Olteanu H, Banerjee R. Redundancy in the pathway for redox regulation of 
mammalian methionine synthase: reductive activation by the dual flavoprotein, 
novel reductase 1. J Biol Chem. 2003;278(40):38310–4.  
35. Castro C, Millian NS, Garrow TA. Liver betaine-homocysteine S-
methyltransferase activity undergoes a redox switch at the active site zinc. Arch 
Biochem Biophys. 2008;472(1):26–33.  
36. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 
1990;1(5):228–37.  
37. Kutzbach C, Stokstad EL. Feedback inhibition of methylene-tetrahydrofolate 
reductase in rat liver by S-adenosylmethionine. Biochim Biophys Acta. 
1967;139(1):217–20.  
38. Kutzbach C, Stokstad EL. Mammalian methylenetetrahydrofolate reductase. 
Partial purification, properties, and inhibition by S-adenosylmethionine. 
Biochim Biophys Acta. 1971;250(3):459–77.  
39. Jencks DA, Mathews RG. Allosteric inhibition of methylenetetrahydrofolate 
reductase by adenosylmethionine. Effects of adenosylmethionine and NADPH 
on the equilibrium between active and inactive forms of the enzyme and on the 
kinetics of approach to equilibrium. J Biol Chem. 1987;262(6):2485–93.  
40. Finkelstein JD, Martin JJ. Inactivation of betaine-homocysteine 
methyltransferase by adenosylmethionine and adenosylethionine. Biochem 
Biophys Res Commun. 1984;118(1):14–9.  
41. Reed MC, Nijhout HF, Neuhouser ML, Gregory JF, Shane B, James SJ, et al. A 
Mathematical Model Gives Insights into Nutritional and Genetic Aspects of 
Folate-Mediated One-Carbon Metabolism. J Nutr. 2006;136(10):2653–61.  
42. Finkelstein JD, Kyle WE, Martin JL, Pick AM. Activation of cystathionine 
synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res 
Commun. 1975;66(1):81–7.  
43. Koracevic D, Djordjevic V. Effect of trypsin, S-adenosylmethionine and 
ethionine on L-serine sulfhydrase activity. Experientia. 1977;33(8):1010–1.  
 80
44. Pey AL, Majtan T, Sanchez-Ruiz JM, Kraus JP. Human cystathionine beta-
synthase (CBS) contains two classes of binding sites for S-adenosylmethionine 
(SAM): complex regulation of CBS activity and stability by SAM. Biochem J. 
2013;449(1):109–21.  
45. Mudd SH, Poole JR. Labile methyl balances for normal humans on various 
dietary regimens. Metabolism. 1975;24(6):721–35.  
46. Mudd SH, Ebert MH, Scriver CR. Labile methyl group balances in the human: 
the role of sarcosine. Metabolism. 1980;29(8):707–20.  
47. Finkelstein JD, Kyle W, Harris BJ. Methionine metabolism in mammals. 
Regulation of homocysteine methyltransferases in rat tissue. Arch Biochem 
Biophys. 1971;146(1):84–92.  
48. Finkelstein JD, Harris BJ, Martin JJ, Kyle WE. Regulation of hepatic betaine-
homocysteine methyltransferase by dietary methionine. Biochem Biophys Res 
Commun. 1982;108(1):344–8.  
49. Finkelstein JD, Martin JJ, Harris BJ, Kyle WE. Regulation of hepatic betaine-
homocysteine methyltransferase by dietary betaine. J Nutr. 1983;113(3):519–21.  
50. Park EI, Garrow TA. Interaction between dietary methionine and methyl donor 
intake on rat liver betaine-homocysteine methyltransferase gene expression and 
organization of the human gene. J Biol Chem. 1999;274(12):7816–24.  
51. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutrition 
Reviews. 2004;62(6 Pt 2):S3–12; discussion S13.  
52. Watkins D, Ru M, Hwang HY, Kim CD, Murray A, Philip NS, et al. 
Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure 
of the MTR gene, genotype diversity, and recognition of a common mutation, 
P1173L. American Journal of Human Genetics. 2002;71(1):143–53.  
53. Hum DW, Bell AW, Rozen R, MacKenzie RE. Primary structure of a human 
trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate 
dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate 
synthetase. J Biol Chem. 1988;263(31):15946–50.  
 81
54. Hum DW, MacKenzie RE. Expression of active domains of a human folate-
dependent trifunctional enzyme in Escherichia coli. Protein Eng. 
1991;4(4):493–500.  
55. Davis SR, Quinlivan EP, Shelnutt KP, Ghandour H, Capdevila A, Coats BS, et 
al. Homocysteine synthesis is elevated but total remethylation is unchanged by 
the methylenetetrahydrofolate reductase 677C->T polymorphism and by dietary 
folate restriction in young women. J Nutr. 2005;135(5):1045–50.  
56. Zeisel SH, Corbin KD. Choline. In: Erdman JW, Macdonald IA, Zeisel SH, 
editors. Present knowledge in nutrition. 10th ed. John Wiley & Sons, Inc.: 
International Life Sciences Institute; 2012. pp. 405–18.  
57. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 
2011;34(1):3–15.  
58. Porter RK, Scott JM, Brand MD. Choline Transport into Rat-Liver 
Mitochondria - Characterization and Kinetics of a Specific Transporter. J Biol 
Chem. 1992;267(21):14637–46.  
59. Zhang J, Blusztajn JK, Zeisel SH. Measurement of the formation of betaine 
aldehyde and betaine in rat-liver mitochondria by a high-pressure liquid-
chromatography radioenzymatic-assay. Biochim Biophys Acta. 
1992;1117(3):333–9.  
60. Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key 
role in methyl group metabolism. Clinical Biochemistry. 2010;43(9):732–44.  
61. Porter DH, Cook RJ, Wagner C. Enzymatic properties of dimethylglycine 
dehydrogenase and sarcosine dehydrogenase from rat liver. Arch Biochem 
Biophys. 1985;243(2):396–407.  
62. Girgis S, Nasrallah IM, Suh JR, Oppenheim E, Zanetti KA, Mastri MG, et al. 
Molecular cloning, characterization and alternative splicing of the human 
cytoplasmic serine hydroxymethyltransferase gene. Gene. 1998;210(2):315–24.  
63. Stover PJ, Chen LH, Suh JR, Stover DM, Keyomarsi K, Shane B. Molecular 
cloning, characterization, and regulation of the human mitochondrial serine 
hydroxymethyltransferase gene. J Biol Chem. 1997;272(3):1842–8.  
 82
64. Scheer JB, Mackey AD, Gregory JF. Activities of Hepatic Cytosolic and 
Mitochondrial Forms of Serine Hydroxymethyltransferase and Hepatic Glycine 
Concentration Are Affected by Vitamin B-6 Intake in Rats. J Nutr. 
2005;135(2):233–8.  
65. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine 
metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–8.  
66. Blumenstein J, Williams GR. The Enzymic N-Methylation of Glycine. Biochem 
Biophys Res Commun. 1960;3(3):259–63.  
67. Wang Y-C, Chen Y-M, Lin Y-J, Liu S-P, Chiang E-PI. GNMT expression 
increases hepatic folate contents and folate-dependent methionine synthase-
mediated homocysteine remethylation. Mol Med. 2011;17(5-6):486–94.  
68. Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: 
reaction mechanism, physiological significance, and hyperglycinemia. Proc Jpn 
Acad Ser B Phys Biol Sci. 2008;84(7):246–63.  
69. Martinez M, Cuskelly GJ, Williamson J, Toth JP, Gregory JF. Vitamin B-6 
Deficiency in Rats Reduces Hepatic Serine Hydroxymethyltransferase and 
Cystathionine -Synthase Activities and Rates of In Vivo Protein Turnover, 
Homocysteine Remethylation and Transsulfuration. J Nutr. 2000;130(5):1115–
23.  
70. Ueland PM, Ulvik A, Rios-Avila L, Midttun O, Gregory JF. Direct and 
functional biomarkers of vitamin B6 status. Annu Rev Nutr. 2015;35:33–70.  
71. Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G. Glycine metabolism in animals 
and humans: implications for nutrition and health. Amino Acids. 
2013;45(3):463–77.  
72. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and 
cardiovascular disease. Annu Rev Med. 1998;49:31–62.  
73. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new 
potential tumor marker. Clin Chim Acta. 2002;322(1-2):21–8.  
74. Steegers-Theunissen RP, Boers GH, Blom HJ, Trijbels FJ, Eskes TK. 
Hyperhomocysteinaemia and recurrent spontaneous abortion or abruptio 
placentae. Lancet. 1992;339(8801):1122–3.  
 83
75. Steegers-Theunissen RP, Boers GH, Blom HJ, Nijhuis JG, Thomas CM, Borm 
GF, et al. Neural tube defects and elevated homocysteine levels in amniotic 
fluid. Am J Obstet Gynecol. 1995;172(5):1436–41.  
76. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, et al. 
Homocysteine metabolism in pregnancies complicated by neural-tube defects. 
Lancet. 1995;345(8943):149–51.  
77. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital 
defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S 
A. 1996;93(26):15227–32.  
78. Cashman KD. Homocysteine and osteoporotic fracture risk: a potential role for 
B vitamins. Nutr Rev. 2005;63(1):29–36.  
79. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum 
homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 
1998;13(4):235–9.  
80. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et 
al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. 
N Engl J Med. 2002;346(7):476–83.  
81. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog 
Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1103–12.  
82. Riggs KM, Spiro 3rd A, Tucker K, Rush D. Relations of vitamin B-12, vitamin 
B-6, folate, and homocysteine to cognitive performance in the Normative Aging 
Study. Am J Clin Nutr. 1996;63(3):306–14.  
83. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, et al. Fasting 
plasma homocysteine levels in the insulin resistance syndrome: the Framingham 
offspring study. Diabetes Care. 2001;24(8):1403–10.  
84. Cho NH, Lim S, Jang HC, Park HK, Metzger BE. Elevated homocysteine as a 
risk factor for the development of diabetes in women with a previous history of 
gestational diabetes mellitus: a 4-year prospective study. Diabetes Care. 
2005;28(11):2750–5.  
85. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects 
of lowering homocysteine levels with B vitamins on cardiovascular disease, 
 84
cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials 
involving 37 485 individuals. Arch Intern Med. 2010;170(18):1622–31.  
86. Joseph J, Handy DE, Loscalzo J. Quo vadis: whither homocysteine research? 
Cardiovasc Toxicol. 2009;9(2):53–63.  
87. Joseph J, Loscalzo J. Methoxistasis: integrating the roles of homocysteine and 
folic Acid in cardiovascular pathobiology. Nutrients. 2013;5(8):3235–56.  
88. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of Folic 
Acid Therapy in Primary Prevention of Stroke Among Adults With 
Hypertension in China. JAMA. 2015;313(13):1325.  
89. Danne O, Mockel M, Lueders C, Mugge C, Zschunke GA, Lufft H, et al. 
Prognostic implications of elevated whole blood choline levels in acute 
coronary syndromes. Am J Cardiol. 2003;91(9):1060–7.  
90. Danne O, Lueders C, Storm C, Frei U, Mockel M. Whole blood choline and 
plasma choline in acute coronary syndromes: prognostic and pathophysiological 
implications. Clin Chim Acta. 2007;383(1-2):103–9.  
91. Schartum-Hansen H, Pedersen ER, Svingen GF, Ueland PM, Seifert R, Ebbing 
M, et al. Plasma choline, smoking, and long-term prognosis in patients with 
stable angina pectoris. Eur J Prev Cardiol. 2014;22(5):606–14.  
92. Svingen GF, Schartum-Hansen H, Pedersen ER, Ueland PM, Tell GS, Mellgren 
G, et al. Prospective Associations of Systemic and Urinary Choline Metabolites 
with Incident Type 2 Diabetes. Clin Chem. 2016;62(5):755–65.  
93. Lever M, George PM, Elmslie JL, Atkinson W, Slow S, Molyneux SL, et al. 
Betaine and secondary events in an acute coronary syndrome cohort. PLoS One. 
2012;7(5):e37883.  
94. Vogel S de, Schneede J, Ueland PM, Vollset SE, Meyer K, Fredriksen A, et al. 
Biomarkers related to one-carbon metabolism as potential risk factors for distal 
colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1726–35.  
95. Svingen GF, Ueland PM, Pedersen EK, Schartum-Hansen H, Seifert R, Ebbing 
M, et al. Plasma dimethylglycine and risk of incident acute myocardial 
infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc 
Biol. 2013;33(8):2041–8.  
 85
96. Svingen GF, Schartum-Hansen H, Ueland PM, Pedersen ER, Seifert R, Ebbing 
M, et al. Elevated plasma dimethylglycine is a risk marker of mortality in 
patients with coronary heart disease. Eur J Prev Cardiol. 2014;22(6):743–52.  
97. Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, et al. 
Prospective evaluation of serum sarcosine and risk of prostate cancer in the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis. 
2013;34(10):2281–5.  
98. Vogel S de, Ulvik A, Meyer K, Ueland PM, Nygard O, Vollset SE, et al. 
Sarcosine and other metabolites along the choline oxidation pathway in relation 
to prostate cancer–a large nested case-control study within the JANUS cohort in 
Norway. Int J Cancer. 2014;134(1):197–206.  
99. DeRatt BN, Ralat MA, Lysne V, Tayyari F, Dhar I, Edison AS, et al. 
Metabolomic Evaluation of the Consequences of Plasma Cystathionine 
Elevation in Adults with Stable Angina Pectoris. J Nutr. 2017;  
100. Dhar I, Svingen GFT, Pedersen ER, DeRatt B, Ulvik A, Strand E, et al. Plasma 
cystathionine and risk of acute myocardial infarction among patients with 
coronary heart disease: Results from two independent cohorts. Int J Cardiol. 
2018;266:24–30.  
101. Dhar I, Svingen GF, Ueland PM, Lysne V, Svenningsson MM, Tell GS, et al. 
Plasma Cystathionine and Risk of Incident Stroke in Patients With Suspected 
Stable Angina Pectoris. J Am Heart Assoc. 2018;7(17).  
102. DeRatt BN, Ralat MA, Kabil O, Chi YY, Banerjee R, Gregory 3rd JF. Vitamin 
B-6 restriction reduces the production of hydrogen sulfide and its biomarkers by 
the transsulfuration pathway in cultured human hepatoma cells. J Nutr. 
2014;144(10):1501–8.  
103. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full 
circle. Nat Rev Cancer. 2013;13(8):572–83.  
104. Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, et al. 
Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With 
Suspected Stable Angina Pectoris. J Am Heart Assoc. 2015;5(1).  
 86
105. Adeva-Andany M, Souto-Adeva G, Ameneiros-Rodríguez E, Fernández-
Fernández C, Donapetry-García C, Domínguez-Montero A. Insulin resistance 
and glycine metabolism in humans. Amino Acids. 2018;50:11–27.  
106. McCormick DB. Riboflavin. In: Erdman JW, Macdonald IA, Zeisel SH, editors. 
Present knowledge in nutrition. 10th ed. John Wiley & Sons, Inc.: International 
Life Sciences Institute; 2012.  
107. Merrill Jr. AH, McCormick DB. Affinity chromatographic purification and 
properties of flavokinase (ATP:riboflavin 5’-phosphotransferase) from rat liver. 
J Biol Chem. 1980;255(4):1335–8.  
108. Oka M, McCormick DB. Complete purification and general characterization of 
FAD synthetase from rat liver. J Biol Chem. 1987;262(15):7418–22.  
109. Hustad S, Mckinley MC, Mcnulty H, Schneede J, Strain JJ, Scott JM, et al. 
Riboflavin, Flavin Mononucleotide, and Flavin Adenine Dinucleotide in Human 
Plasma and Erythrocytes at Baseline and after Low-Dose Riboflavin 
Supplementation. Clin Chem. 2002 Sep;48(9):1571–7.  
110. Penberthy TW, Kirkland JB. Niacin. In: Erdman JW, Macdonald IA, Zeisel SH, 
editors. Present knowledge in nutrition. 10th ed. John Wiley & Sons, Inc.: 
International Life Sciences Institute; 2012. pp. 293–306.  
111. Nejabati HR, Mihanfar A, Pezeshkian M, Fattahi A, Latifi Z, Safaie N, et al. 
N1-methylnicotinamide (MNAM) as a guardian of cardiovascular system. J Cell 
Physiol. 2018;233(10):6386–94.  
112. Le Floc’h N, Otten W, Merlot E. Tryptophan metabolism, from nutrition to 
potential therapeutic applications. Amino Acids. 2011 Nov;41(5):1195–205.  
113. Stavrum AK, Heiland I, Schuster S, Puntervoll P, Ziegler M. Model of 
tryptophan metabolism, readily scalable using tissue-specific gene expression 
data. J Biol Chem. 2013;288(48):34555–66.  
114. Growth-promoting Activity of Pyrazinoic Acid, a Putative Active Compound of 
Antituberculosis Drug Pyrazinamide, in Niacin-deficient Rats through the 
Inhibition of ACMSD Activity. Biosci Biotechnol Biochem. 2002 
Jan;66(7):1435–41.  
 87
115. Katsyuba E, Mottis A, Zietak M, De Franco F, Velpen V van der, Gariani K, et 
al. De novo NAD+ synthesis enhances mitochondrial function and improves 
health. Nature. 2018;563(7731):354–9.  
116. McCormick DB. Two interconnected B vitamins: riboflavin and pyridoxine. 
Physiol Rev. 1989;69(4):1170–98.  
117. Silva VR da, Russel KA, Gregory III JF. Vitamin B6. In: Erdman JW, 
Macdonald IA, Zeisel SH, editors. Present knowledge in nutrition. 10th ed. John 
Wiley & Sons, Inc.: International Life Sciences Institute; 2012. pp. 307–20.  
118. Ulvik A, Theofylaktopoulou D, Midttun O, Nygard O, Eussen SJ, Ueland PM. 
Substrate product ratios of enzymes in the kynurenine pathway measured in 
plasma as indicators of functional vitamin B-6 status. Am J Clin Nutr. 
2013;98(4):934–40.  
119. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating 
vitamin B(6) is associated with elevation of the inflammation marker C-reactive 
protein independently of plasma homocysteine levels. Circulation. 
2001;103(23):2788–91.  
120. Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of 
inflammation in a population of U.S. adults. J Nutr. 2012 Jul;142(7):1280–5.  
121. Paul L, Ueland PM, Selhub J. Mechanistic perspective on the relationship 
between pyridoxal 5’-phosphate and inflammation. Nutr Rev. 2013;71(4):239–
44.  
122. Ueland PM, McCann A, Midttun O, Ulvik A. Inflammation, vitamin B6 and 
related pathways. Mol Aspects Med. 2017;53:10–27.  
123. Ulvik A, Midttun O, Pedersen ER, Eussen SJ, Nygard O, Ueland PM. Evidence 
for increased catabolism of vitamin B-6 during systemic inflammation. Am J 
Clin Nutr. 2014;  
124. Bailey LB, Caudill MA. Folate. In: Erdman JW, Macdonald IA, Zeisel SH, 
editors. Present knowledge in nutrition. 10th ed. John Wiley & Sons, Inc.: 
International Life Sciences Institute; 2012.  
 88
125. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P. Effects 
and safety of periconceptional oral folate supplementation for preventing birth 
defects. Cochrane Database Syst Rev. 2015;(12):CD007950.  
126. Herbert V, Larrabee AR, Buchanan JM. Studies on identification of a folate 
compound of human serum. J Clin Invest. 1962;41(5):1134 –&.  
127. Sweeney MR, McPartlin J, Scott J. Folic acid fortification and public health: 
Report on threshold doses above which unmetabolised folic acid appear in 
serum. BMC Public Health. 2007;7:41.  
128. Bailey RL, Mills JL, Yetley EA, Gahche JJ, Pfeiffer CM, Dwyer JT, et al. 
Unmetabolized serum folic acid and its relation to folic acid intake from diet 
and supplements in a nationally representative sample of adults aged ≥60 y in 
the United States. Am J Clin Nutr. 2010;92(2):383.  
129. Pfeiffer CM, Sternberg MR, Fazili Z, Yetley EA, Lacher DA, Bailey RL, et al. 
Unmetabolized Folic Acid Is Detected in Nearly All Serum Samples from US 
Children, Adolescents, and Adults. J Nutr. 2015;145(3):520–31.  
130. Plumptre L, Masih SP, Ly A, Aufreiter S, Sohn K-J, Croxford R, et al. High 
concentrations of folate and unmetabolized folic acid in a cohort of pregnant 
Canadian women and umbilical cord blood. Am J Clin Nutr. 2015;102(4):848–
57.  
131. Pentieva K, Selhub J, Paul L, Molloy AM, McNulty B, Ward M, et al. Evidence 
from a Randomized Trial That Exposure to Supplemental Folic Acid at 
Recommended Levels during Pregnancy Does Not Lead to Increased 
Unmetabolized Folic Acid Concentrations in Maternal or Cord Blood. J Nutr. 
2016;146(3):494–500.  
132. Hannibal L, Lysne V, Bjørke-Monsen A-L, Behringer S, Grünert SC, 
Spiekerkoetter U, et al. Biomarkers and algorithms for the diagnosis of vitamin 
B12deficiency. Front Mol Biosci. 2016;  
133. Stabler SP. Vitamin B12. In: Erdman JW, Macdonald IA, Zeisel SH, editors. 
Present knowledge in nutrition. 10th ed. John Wiley & Sons, Inc.: International 
Life Sciences Institute; 2012. pp. 343–58.  
 89
134. Kornerup LS, Juul CB, Fedosov SN, Heegaard CW, Greibe E, Nexo E. 
Absorption and retention of free and milk protein-bound cyano- and 
hydroxocobalamins. An experimental study in rats. Biochimie. 2016;126:57–62.  
135. Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be 
superior to cyano- and hydroxyl-cobalamin in prevention or treatment of 
cobalamin deficiency. Mol Nutr Food Res. 2015;59(7):1364–72.  
136. Kornerup LS, Fedosov SN, Juul CB, Greibe E, Heegaard CW, Nexo E. Tissue 
distribution of oral vitamin B12 is influenced by B12 status and B12 form: an 
experimental study in rats. Eur J Nutr. 2017;  
137. Carmel R. Current concepts in cobalamin deficiency. Annual Review of 
Medicine. 2000;51:357–75.  
138. Lysne V, Strand E, Svingen GF, Bjorndal B, Pedersen ER, Midttun O, et al. 
Peroxisome Proliferator-Activated Receptor Activation is Associated with 
Altered Plasma One-Carbon Metabolites and B-Vitamin Status in Rats. 
Nutrients. 2016;8(1).  
139. Solomon LR. Cobalamin-responsive disorders in the ambulatory care setting: 
unreliability of cobalamin, methylmalonic acid, and homocysteine testing. 
Blood. 2005;105(3):978–85; author reply 1137.  
140. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. 
British Journal of Haematology. 2014;166:496–513.  
141. Obeid R, Jung J, Falk J, Herrmann W, Geisel J, Friesenhahn-Ochs B, et al. 
Serum vitamin B12 not reflecting vitamin B12 status in patients with type 2 
diabetes. Biochimie. 2013;95(5):1056–61.  
142. Lysne V, Bjørndal B, Grinna ML, Midttun Ø, Ueland PM, Berge RK, et al. 
PPARα activation influences plasma one-carbon metabolites and B-vitamin 
status in rats. submitted manuscript. 2019.  
143. Vogiatzoglou A, Oulhaj A, Smith AD, Nurk E, Drevon CA, Ueland PM, et al. 
Determinants of plasma methylmalonic acid in a large population: implications 
for assessment of vitamin B12 status. Clin Chem. 2009;55(12):2198–206.  
144. Molloy AM, Pangilinan F, Mills JL, Shane B, O’Neill MB, McGaughey DM, et 
al. A Common Polymorphism in HIBCH Influences Methylmalonic Acid 
 90
Concentrations in Blood Independently of Cobalamin. Am J Hum Genet. 
2016;98(5):869–82.  
145. Olsen T, Øvrebø B, Turner C, Bastani N, Refsum H, Vinknes K, et al. 
Combining Dietary Sulfur Amino Acid Restriction with Polyunsaturated Fatty 
Acid Intake in Humans: A Randomized Controlled Pilot Trial. Nutrients. 
2018;10(12):1822.  
146. Lind MV, Lauritzen L, Pedersen O, Vestergaard H, Stark KD, Hansen T, et al. 
Higher intake of fish and fat is associated with lower plasma s-
adenosylhomocysteine: a cross-sectional study. Nutr Res. 2017;46:78–87.  
147. Bjørndal B, Bruheim I, Lysne V, Ramsvik MS, Ueland PM, Nordrehaug JE, et 
al. Plasma choline, homocysteine and vitamin status in healthy adults 
supplemented with krill oil: a pilot study. Scand J Clin Lab Invest. 2018;78(7-
8):527–32.  
148. Ulven SM, Christensen JJ, Nygård O, Svardal A, Leder L, Ottestad I, et al. 
Using metabolic profiling and gene expression analyses to explore molecular 
effects of replacing saturated fat with polyunsaturated fat—a randomized 
controlled dietary intervention study. Am J Clin Nutr. 2019 Apr;  
149. Ross AB, Zangger A, Guiraud SP. Cereal foods are the major source of betaine 
in the Western diet – Analysis of betaine and free choline in cereal foods and 
updated assessments of betaine intake. Food Chem. 2014;145:859–65.  
150. Ross AB, Bruce SJ, Blondel-Lubrano A, Oguey-Araymon S, Beaumont M, 
Bourgeois A, et al. A whole-grain cereal-rich diet increases plasma betaine, and 
tends to decrease total and LDL-cholesterol compared with a refined-grain diet 
in healthy subjects. Br J Nutr. 2011;105(10):1492–502.  
151. Sparks JD, Collins HL, Chirieac DV, Cianci J, Jokinen J, Sowden MP, et al. 
Hepatic very-low-density lipoprotein and apolipoprotein B production are 
increased following in vivo induction of betaine-homocysteine S-
methyltransferase. Biochem J. 2006;395(2):363–71.  
152. Dahlhoff C, Desmarchelier C, Sailer M, Furst RW, Haag A, Ulbrich SE, et al. 
Hepatic methionine homeostasis is conserved in C57BL/6N mice on high-fat 
 91
diet despite major changes in hepatic one-carbon metabolism. PloS One. 
2013;8(3):e57387.  
153. Petzke KJ, Albrecht V, Przybilski H. The Influence of High Glycine Diets on 
the Activity of Glycine-Catabolizing Enzymes and on Glycine Catabolism in 
Rats. J Nutr. 1986 May;116(5):742–50.  
154. Ebbing M, Bonaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, et 
al. Combined analyses and extended follow-up of two randomized controlled 
homocysteine-lowering B-vitamin trials. J Intern Med. 2010;268(4):367–82.  
155. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary 
protein restriction of pregnant rats induces and folic acid supplementation 
prevents epigenetic modification of hepatic gene expression in the offspring. J 
Nutr. 2005;135(6):1382–6.  
156. Issemann I, Green S. Activation of a member of the steroid hormone receptor 
superfamily by peroxisome proliferators. Nature. 1990;347(6294).  
157. Bugge A, Mandrup S. Molecular Mechanisms and Genome-Wide Aspects of 
PPAR Subtype Specific Transactivation. PPAR Res. 2010;2010.  
158. Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their 
ligands: nutritional and clinical implications - a review. Nutr J. 2014;13(1).  
159. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, et al. 
Identification of a physiologically relevant endogenous ligand for PPARalpha in 
liver. Cell. 2009;138(3):476–88.  
160. Contreras AV, Torres N, Tovar AR. PPAR-alpha as a key nutritional and 
environmental sensor for metabolic adaptation. Adv Nutr. 2013;4(4):439–52.  
161. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA. Interaction 
of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc 
Natl Acad Sci U S A. 1993;90(4).  
162. Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. 
FEBS Lett. 2008;582(1).  
163. Almeida NR, Conda‐Sheridan M. A review of the molecular design and 
biological activities of RXR agonists. Med Res Rev. 2019;med.21578.  
 92
164. Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome proliferator-
activated receptor alpha target genes. PPAR Res. 2010;2010.  
165. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, 
hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.  
166. Kersten S, Stienstra R. The role and regulation of the peroxisome proliferator 
activated receptor alpha in human liver. Biochimie. 2017 May;136:75–84.  
167. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, et al. 
"New" hepatic fat activates PPARalpha to maintain glucose, lipid, and 
cholesterol homeostasis. Cell Metab. 2005;1(5):309–22.  
168. Kersten S. Integrated physiology and systems biology of PPAR. Mol Metab. 
2014;3(4):354–71.  
169. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, et al. The 
peroxisome proliferator-activated receptor alpha regulates amino acid 
metabolism. FASEB J. 2001;15(11):1971–8.  
170. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND. 
Beyond lipids, pharmacological PPARalpha activation has important effects on 
amino acid metabolism as studied in the rat. Am J Physiol Endocrinol Metab. 
2007;292(4):E1157–65.  
171. Aleman G, Ortiz V, Contreras AV, Quiroz G, Ordaz-Nava G, Langley E, et al. 
Hepatic amino acid-degrading enzyme expression is downregulated by natural 
and synthetic ligands of PPARalpha in rats. J Nutr. 2013;143(8):1211–8.  
172. Kobayashi R, Murakami T, Obayashi M, Nakai N, Jaskiewicz J, Fujiwara Y, et 
al. Clofibric acid stimulates branched-chain amino acid catabolism by three 
mechanisms. Arch Biochem Biophys. 2002;407(2):231–40.  
173. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez 
FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates 
the vascular inflammatory gene response by negative cross-talk with 
transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274(45):32048–
54.  
174. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and 
inflammation. Trends Endocrinol Metab. 2012;23(7):351–63.  
 93
175. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. 
Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects 
afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J 
Neurotrauma. 2007;24(7):1119–31.  
176. Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, et al. 
PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis 
in rats. Biochem Biophys Res Commun. 2004;324(2):697–704.  
177. Gelosa P, Banfi C, Gianella A, Brioschi M, Pignieri A, Nobili E, et al. 
Peroxisome proliferator-activated receptor α agonism prevents renal damage 
and the oxidative stress and inflammatory processes affecting the brains of 
stroke-prone rats. Journal of Pharmacology and Experimental Therapeutics. 
2010;335(2):324–31.  
178. Zandbergen F, Plutzky J. PPAR in atherosclerosis and inflammation. Biochim 
Biophys Acta. 2007;1771(8):972–82.  
179. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. 
Peroxisome proliferator-activated receptor alpha mediates the adaptive response 
to fasting. J Clin Invest. 1999;103(11):1489–98.  
180. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne 
B, et al. Expression of the peroxisome proliferator-activated receptor alpha gene 
is stimulated by stress and follows a diurnal rhythm. J Biol Chem. 
1996;271(3):1764–9.  
181. Sanderson LM, Degenhardt T, Koppen A, Kalkhoven E, Desvergne B, Müller 
M, et al. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) 
but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol Cell 
Biol. 2009;29(23):6257–67.  
182. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty 
acids, and eicosanoids are ligands for peroxisome proliferator-activated 
receptors alpha and delta. Proc Natl Acad Sci U S A. 1997;94(9):4312–7.  
183. Ciana P, Biserni A, Tatangelo L, Tiveron C, Sciarroni AF, Ottobrini L, et al. A 
Novel Peroxisome Proliferator-Activated Receptor Responsive Element-
Luciferase Reporter Mouse Reveals Gender Specificity of Peroxisome 
 94
Proliferator-Activated Receptor Activity in Liver. Molecular Endocrinology. 
2007;21(2):388–400.  
184. Wang L, Chen L, Tan Y, Wei J, Chang Y, Jin T, et al. Betaine supplement 
alleviates hepatic triglyceride accumulation of apolipoprotein E deficient mice 
via reducing methylation of peroxisomal proliferator-activated receptor alpha 
promoter. Lipids in Health and Disease. 2013;12:34.  
185. Veum VL, Laupsa-Borge J, Eng O, Rostrup E, Larsen TH, Nordrehaug JE, et al. 
Visceral adiposity and metabolic syndrome after very high-fat and low-fat 
isocaloric diets: a randomized controlled trial. Am J Clin Nutr. 2016;  
186. Tay J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Noakes M, 
Buckley JD, et al. Effects of an energy-restricted low-carbohydrate, high 
unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in 
type 2 diabetes: A 2-year randomized clinical trial. Diabetes Obes and Metab. 
2018 Apr;20(4):858–71.  
187. Duval C, Muller M, Kersten S. PPARalpha and dyslipidemia. Biochim Biophys 
Acta. 2007;1771(8):961–71.  
188. Raspe E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J, 
et al. Modulation of rat liver apolipoprotein gene expression and serum lipid 
levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J Lipid 
Res. 1999;40(11).  
189. Vigerust NF, Cacabelos D, Burri L, Berge K, Wergedahl H, Christensen B, et 
al. Fish oil and 3-thia fatty acid have additive effects on lipid metabolism but 
antagonistic effects on oxidative damage when fed to rats for 50 weeks. The 
Journal of Nutritional Biochemistry. 2012;23(11):1384–93.  
190. Dyroy E, Yndestad A, Ueland T, Halvorsen B, Damas JK, Aukrust P, et al. 
Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome 
proliferator-activated receptor alpha-dependent and -independent pathways. 
Arterioscler Thromb Vasc Biol. 2005;25(7):1364–9.  
191. Madsen L, Guerre-Millo M, Flindt EN, Berge K, Tronstad KJ, Bergene E, et al. 
Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin 
resistance. J Lipid Res. 2002;43(5):742–50.  
 95
192. Bjorndal B, Brattelid T, Strand E, Vigerust NF, Svingen GF, Svardal A, et al. 
Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino 
acid and carnitine metabolism in rats. PLoS One. 2013;8(6):e66926.  
193. Wensaas AJ, Rustan AC, Rokling-Andersen MH, Caesar R, Jensen J, Kaalhus 
O, et al. Dietary supplementation of tetradecylthioacetic acid increases feed 
intake but reduces body weight gain and adipose depot sizes in rats fed on high-
fat diets. Diabetes Obes Metab. 2009;11(11):1034–49.  
194. Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role 
in rodent liver cancer and species differences. J Mol Endocrinol. 1999;22(1):1–
8.  
195. Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-
alpha and liver cancer: where do we stand? J Mol Med (Berl). 2005;83(10):774–
85.  
196. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, et al. 
Differential gene regulation in human versus rodent hepatocytes by peroxisome 
proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce 
peroxisome proliferation-associated genes in human cells independently of the 
level of receptor expresso. J Biol Chem. 2001;276(34):31521–7.  
197. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, et al. 
Diminished hepatocellular proliferation in mice humanized for the nuclear 
receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 
2004;64(11):3849–54.  
198. Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ. Differential 
susceptibility of mice humanized for peroxisome proliferator-activated receptor 
alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis. 
2006;27(5):1074–80.  
199. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ. The PPAR alpha-
humanized mouse: a model to investigate species differences in liver toxicity 
mediated by PPAR alpha. Toxicol Sci. 2008;101(1):132–9.  
 96
200. Gonzalez FJ, Shah YA. PPAR alpha: Mechanism of species differences and 
hepatocarcinogenesis of peroxisome proliferators. Toxicology. 2008;246(1):2–
8.  
201. de la Rosa Rodriguez MA, Sugahara G, Hooiveld GJEJ, Ishida Y, Tateno C, 
Kersten S. The whole transcriptome effects of the PPAR agonist fenofibrate 
on livers of hepatocyte humanized mice. BMC Genomics. 2018 Jun;19(1):443.  
202. Ntaios G, Savopoulos C, Chatzopoulos S, Mikhailidis D, Hatzitolios A. 
Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a 
systematic review and metaanalysis. Atherosclerosis. 2011;214(1):11–9.  
203. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin 
Vasc Med. 2005;5(2):124–39.  
204. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on 
plasma homocysteine. The Lancet. 2001;358(9275):39–40.  
205. Fenofibrate increases the l-arginine:ADMA ratio by increase of l-arginine 
concentration but has no effect on ADMA concentration. Atherosclerosis. 
2004;173(2):239–44.  
206. Vitamin supplementation can markedly reduce the homocysteine elevation 
induced by fenofibrate. Atherosclerosis. 2001 Sep;158(1):161–4.  
207. Mayer Jr. O, Simon J, Holubec L, Pikner R, Subrt I. Fenofibrate-induced 
hyperhomocysteinemia may be prevented by folate co-administration. Eur J 
Clin Pharmacol. 2003;59(5-6):367–71.  
208. Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C. Comparative gene 
expression profiles induced by PPARgamma and PPARalpha/gamma agonists 
in rat hepatocytes. Toxicol Appl Pharmacol. 2011;254(1):18–31.  
209. Lever M, George PM, Slow S, Elmslie JL, Scott RS, Richards AM, et al. 
Fibrates may cause an abnormal urinary betaine loss which is associated with 
elevations in plasma homocysteine. Cardiovasc Drugs Ther. 2009;23(5):395–
401.  
210. Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, Slow S, et al. 
Plasma lipids and betaine are related in an acute coronary syndrome cohort. 
PLoS One. 2011;6(7):e21666.  
 97
211. Lever M, McEntyre CJ, George PM, Slow S, Elmslie JL, Lunt H, et al. Extreme 
urinary betaine losses in type 2 diabetes combined with bezafibrate treatment 
are associated with losses of dimethylglycine and choline but not with increased 
losses of other osmolytes. Cardiovasc Drugs Ther. 2014;28(5):459–68.  
212. Lever M, McEntyre CJ, George PM, Slow S, Chambers ST, Foucher C. 
Fenofibrate causes elevation of betaine excretion but not excretion of other 
osmolytes by healthy adults. J Clin Lipidol. 2014;8(4):433–40.  
213. Wrzesinski K, Leon IR, Kulej K, Sprenger RR, Bjorndal B, Christensen BJ, et 
al. Proteomics identifies molecular networks affected by tetradecylthioacetic 
acid and fish oil supplemented diets. J Proteomics. 2013;84.  
214. Chu R, Lim H, Brumfield L, Liu H, Herring C, Ulintz P, et al. Protein profiling 
of mouse livers with peroxisome proliferator-activated receptor alpha activation. 
Mol Cell Biol. 2004;24(14):6288–97.  
215. Ericsson A, Turner N, Hansson GI, Wallenius K, Oakes ND. Pharmacological 
PPARalpha activation markedly alters plasma turnover of the amino acids 
glycine, serine and arginine in the rat. PLoS One. 2014;9(12):e113328.  
216. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al. 
Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced 
toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37(4):521–35.  
217. Ringeissen S, Connor SC, Brown HR, Sweatman BC, Hodson MP, Kenny SP, 
et al. Potential urinary and plasma biomarkers of peroxisome proliferation in the 
rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-
carboxamide by 1H nuclear magnetic resonance and high performance liquid 
chromatography. Biomarkers. 2003;8(3-4):240–71.  
218. Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. Metabolomic and genetic 
analysis of biomarkers for peroxisome proliferator-activated receptor alpha 
expression and activation. Mol Endocrinol. 2007;21(9):2136–51.  
219. Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, et 
al. Tryptophan-NAD+ pathway metabolites as putative biomarkers and 
predictors of peroxisome proliferation. Arch Toxicol. 2005;79(4):208–23.  
 98
220. Shin M, Mori Y, Kimura A, Fujita Y, Yoshida K, Sano K, et al. NAD+ 
biosynthesis and metabolic fluxes of tryptophan in hepatocytes isolated from 
rats fed a clofibrate-containing diet. Biochem Pharmacol. 1996;52(2):247–52.  
221. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisome-proliferator 
regulates key enzymes of the tryptophan-NAD+ pathway. Toxicol Appl 
Pharmacol. 1999;158(1):71–80.  
222. Shin M, Kim I, Inoue Y, Kimura S, Gonzalez FJ. Regulation of mouse hepatic 
alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key 
enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by 
hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor 
a. Mol Pharmacol. 2006;70(4):1281–90.  
223. Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, et 
al. Different skeletal effects of the peroxisome proliferator activated receptor 
(PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. 
BMC Endocr Disord. 2009;9(10).  
224. Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, 
et al. The peroxisome proliferator-activated receptor (PPAR) alpha agonist 
fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone 
exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord. 2011;11:11.  
225. Ueland PM, Midttun O, Windelberg A, Svardal A, Skalevik R, Hustad S. 
Quantitative profiling of folate and one-carbon metabolism in large-scale 
epidemiological studies by mass spectrometry. Clinical Chemistry and 
Laboratory Medicine. 2007;45(12):1737–45.  
226. Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related 
to B-vitamin status, tryptophan metabolism and inflammation in human plasma 
by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass 
Spectrom. 2009;23(9):1371–9.  
227. Midttun O, Kvalheim G, Ueland PM. High-throughput, low-volume, 
multianalyte quantification of plasma metabolites related to one-carbon 
metabolism using HPLC-MS/MS. Anal Bioanal Chem. 2013;405(6):2009–17.  
 99
228. Midttun O, McCann A, Aarseth O, Krokeide M, Kvalheim G, Meyer K, et al. 
Combined Measurement of 6 Fat-Soluble Vitamins and 26 Water-Soluble 
Functional Vitamin Markers and Amino Acids in 50 muL of Serum or Plasma 
by High-Throughput Mass Spectrometry. Anal Chem. 2016;88(21):10427–36.  
229. Kelleher BP, Broin SD. Microbiological assay for vitamin B12 performed in 96-
well microtitre plates. J Clin Pathol. 1991;44(7):592–5.  
230. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell 
folate using cryopreserved, microtiter plate method. Methods Enzymol. 
1997;281:43–53.  
231. Christensen BJ, Berge K, Wergedahl H, Bohov P, Berge RK, Svendsen E, et al. 
Bioactive fatty acids reduce development of gastric cancer following 
duodenogastric reflux in rats. Surg Sci. 2012;3(1).  
232. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical 
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical 
Society Series B-Methodological. 1995;57(1):289–300.  
233. Strand E, Lysne V, Grinna ML, Bohov P, Svardal A, Nygård O, et al. Short-
term activation of peroxisome proliferator-activated receptors α and γ induce 
tissue specific effects on lipid metabolism and fatty acid composition in male 
Wistar rats. PPAR Res. 2019;2016.  
234. Limpert E, Stahel WA, Abbt M. Log-normal distributions across the sciences: 
Keys and clues. BioScience. 2001;51(5):341–52.  
235. Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9.  
236. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in 
epidemiologic studies. American Journal of Clinical Nutrition. 1997;65(4 
Suppl):1220S–1228S; discussion 1229S–31S.  
237. Benoit K. Linear Regression Models with Logarithmic Transformations 
[Internet]. 2011. Available from: 
https://kenbenoit.net/assets/courses/ME104/logmodels2.pdf 
238. Wilke CO. Ungeviz: Tools for visualizing uncertainty with ggplot2. 2019.  
239. Song M, Giovannucci E. Substitution analysis in nutritional epidemiology: 
proceed with caution. Eur J Epidemiol. 2018;33(2):137–40.  
 100
240. SPSS Inc. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY; 2012.  
241. R Core Team. R: A language and environment for statistical computing. Vienna, 
Austria: R Foundation for Statistical Computing; 2018.  
242. Wickham H. Tidyverse: Easily install and load the ’tidyverse’. 2017.  
243. Robinson D, Hayes A. Broom: Convert statistical analysis objects into tidy 
tibbles. 2018.  
244. Wickham H, Henry L. Tidyr: Easily tidy data with ’spread()’ and ’gather()’ 
functions. 2019.  
245. Wickham H, François R, Henry L, Müller K. Dplyr: A grammar of data 
manipulation. 2018.  
246. Wickham H. Forcats: Tools for working with categorical variables (factors). 
2018.  
247. Wickham H. Ggplot2: Elegant graphics for data analysis. Springer-Verlag New 
York; 2016.  
248. Wickham H, Miller E. Haven: Import and export ’spss’, ’stata’ and ’sas’ files. 
2018.  
249. Bache SM, Wickham H. Magrittr: A forward-pipe operator for r. 2014.  
250. Henry L, Wickham H. Purrr: Functional programming tools. 2018.  
251. Henry L, Wickham H. Rlang: Functions for base types and core r and 
’tidyverse’ features. 2019.  
252. Wickham H. Stringr: Simple, consistent wrappers for common string operations. 
2018.  
253. Torchiano M. Effsize: Efficient effect size computation. 2018.  
254. Gordon M, Lumley T. Forestplot: Advanced forest plot using ’grid’ graphics. 
2017.  
255. Tierney N, Cook D, McBain M, Fay C. Naniar: Data structures, summaries, and 
visualisations for missing data. 2019.  
256. Tierney N. Visdat: Visualising whole data frames. JOSS. 2017;2(16):355.  
257. Gohel D. Flextable: Functions for tabular reporting. 2019.  
258. Gohel D. Officer: Manipulation of microsoft word and powerpoint documents. 
2019.  
 101
259. Allaire J, Xie Y, McPherson J, Luraschi J, Ushey K, Atkins A, et al. 
Rmarkdown: Dynamic documents for r. 2019.  
260. Johnson M. Laboratory Mice and Rats. Materials and Methods [Internet]. 2012 
Oct;2. Available from: http://www.labome.com/method/Laboratory-Mice-and-
Rats.html 
261. The 3Rs | NC3Rs [Internet]. Available from: https://www.nc3rs.org.uk/the-3rs 
262. MacArthur Clark J. The 3Rs in research: a contemporary approach to 
replacement, reduction and refinement. Br J Nutr. 2018;120(s1):S1–7.  
263. Sneddon LU, Halsey LG, Bury NR. Considering aspects of the 3Rs principles 
within experimental animal biology. J Exp Biol. 2017 Sep;220(Pt 17):3007–16.  
264. Festing MFW, Nevalainen T. The Design and Statistical Analysis of Animal 
Experiments: Introduction to this Issue. ILAR J. 2014 Dec;55(3):379–82.  
265. Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological 
research: issues and perspectives. Future Science OA. 2015;1(4).  
266. Maki KC, Slavin JL, Rains TM, Kris-Etherton PM. Limitations of observational 
evidence: implications for evidence-based dietary recommendations. Adv Nutr. 
2014;5(1):7–15.  
267. Fewell Z, Davey Smith G, Sterne JAC. The Impact of Residual and 
Unmeasured Confounding in Epidemiologic Studies: A Simulation Study. Am J 
Epidemiol. 2007;166(6):646–55.  
268. Brakenhoff TB, Smeden M van, Visseren FLJ, Groenwold RHH. Random 
measurement error: Why worry? An example of cardiovascular risk factors. 
PLOS ONE. 2018;13(2):e0192298.  
269. Smith GD, Phillips AN. Confounding in epidemiological studies: why 
"independent" effects may not be all they seem. BMJ. 1992;305(6856):757–9.  
270. Smith GD, Phillips A. Declaring independence: why we should be cautious. J 
Epidemiol Community Health. 1990;44(4):257–8.  
271. Ding P, VanderWeele TJ. Sensitivity Analysis Without Assumptions. 
Epidemiology. 2016;27(3):368–77.  
272. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: 
Introducing the E-Value. Ann Intern Med. 2017;  
 102
273. Galobardes B, Morabia A, Bernstein MS. Diet and socioeconomic position: 
does the use of different indicators matter? Int J Epidemiol. 2001;30(2):334–40.  
274. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. 
Mortality and cardiovascular events in patients treated with homocysteine-
lowering B vitamins after coronary angiography: a randomized controlled trial. 
JAMA. 2008;300(7):795–804.  
275. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health. 
2004;58(8):635.  
276. Manger MS, Strand E, Ebbing M, Seifert R, Refsum H, Nordrehaug JE, et al. 
Dietary intake of n-3 long-chain polyunsaturated fatty acids and coronary events 
in Norwegian patients with coronary artery disease. Am J Clin Nutr. 
2010;92(1):244–51.  
277. Mendez MA. Invited commentary: Dietary misreporting as a potential source of 
bias in diet-disease associations: future directions in nutritional epidemiology 
research. Am J Epidemiol. 2015;181(4):234–6.  
278. Rhee JJ, Willett WC. Rhee and Willett respond to "dietary misreporting". Am J 
Epidemiol. 2015;181(4):237.  
279. Rhee JJ, Sampson L, Cho E, Hughes MD, Hu FB, Willett WC. Comparison of 
methods to account for implausible reporting of energy intake in epidemiologic 
studies. Am J Epidemiol. 2015;181(4):225–33.  
280. Loken E, Gelman A. Measurement error and the replication crisis. Science. 
2017 Feb;355(6325):584–5.  
281. Nes M, Frost Andersen L, Solvoll K, Sandstad B, Hustvedt BE, Lovo A, et al. 
Accuracy of a quantitative food frequency questionnaire applied in elderly 
Norwegian women. Eur J Clin Nutr. 1992;46(11):809–21.  
282. Andersen LF, Solvoll K, Johansson LR, Salminen I, Aro A, Drevon CA. 
Evaluation of a food frequency questionnaire with weighed records, fatty acids, 
and alpha-tocopherol in adipose tissue and serum. Am J Epidemiol. 
1999;150(1):75–87.  
283. Archer E, Pavela G, Lavie CJ. The Inadmissibility of What We Eat in America 
and NHANES Dietary Data in Nutrition and Obesity Research and the 
 103
Scientific Formulation of National Dietary Guidelines. Mayo Clin Proc. 
2015;90(7):911–26.  
284. Ioannidis JP. Implausible results in human nutrition research. BMJ. 
2013;347:f6698.  
285. Archer E, Marlow ML, Lavie CJ. The Fatal Flaws of Food Frequency 
Questionnaires and Other Memory-Based Dietary Assessment Methods. J Clin 
Epidemiol. 2018;  
286. Archer E, Marlow ML, Lavie CJ. Controversy and Debate: Memory-Based 
Dietary Assessment Methods Paper #3. J Clin Epidemiol. 2018;  
287. Subar AF, Freedman LS, Tooze JA, Kirkpatrick SI, Boushey C, Neuhouser ML, 
et al. Addressing Current Criticism Regarding the Value of Self-Report Dietary 
Data. J Nutr. 2015;  
288. Martin-Calvo N, Martinez-Gonzalez MA. Controversy and Debate: Memory 
based Methods Paper 4. J Clin Epidemiol. 2018;  
289. Martin-Calvo N, Martinez-Gonzalez MA. Controversy and Debate: Memory 
based Methods Paper 2. J Clin Epidemiol. 2018;  
290. Kipnis V, Subar AF, Midthune D, Freedman LS, Ballard-Barbash R, Troiano 
RP, et al. Structure of dietary measurement error: results of the OPEN 
biomarker study. Am J Epidemiol. 2003;158(1):14–6.  
291. Freedman LS, Commins JM, Moler JE, Arab L, Baer DJ, Kipnis V, et al. Pooled 
results from 5 validation studies of dietary self-report instruments using 
recovery biomarkers for energy and protein intake. Am J Epidemioll. 
2014;180(2):172–88.  
292. Lysne V, Olsen T. Feilkilder i ernæringsepidemiologi. Norsk Tidsskrift for 
Ernæring. 2018;(2).  
293. Freedman LS, Commins JM, Moler JE, Willett W, Tinker LF, Subar AF, et al. 
Pooled Results From 5 Validation Studies of Dietary Self-Report Instruments 
Using Recovery Biomarkers for Potassium and Sodium Intake. Am J 
Epidemiol. 2015;181(7):473–87.  
 104
294. Freedman LS, Schatzkin A, Midthune D, Kipnis V. Dealing with dietary 
measurement error in nutritional cohort studies. J Natl Cancer Inst. 
2011;103(14):1086–92.  
295. Kipnis V, Freedman LS, Brown CC, Hartman AM, Schatzkin A, Wacholder S. 
Effect of Measurement Error on Energy-Adjustment Models in Nutritional 
Epidemiology. Am J Epidemiol. 1997;146(10):842–55.  
296. Jakobsen MU, O’Reilly EJ, Heitmann BL, Pereira MA, Balter K, Fraser GE, et 
al. Major types of dietary fat and risk of coronary heart disease: a pooled 
analysis of 11 cohort studies. Am J Clin Nutr. 2009;89(5):1425–32.  
297. Hjartåker A, Andersen LF, Lund E. Comparison of diet measures from a food-
frequency questionnaire with measures from repeated 24-hour dietary recalls. 
The Norwegian Women and Cancer Study. Public Health Nutr. 
2007;10(10):1094–103.  
298. Andersen LF, Tomten H, Haggarty P, Lovo A, Hustvedt BE. Validation of 
energy intake estimated from a food frequency questionnaire: a doubly labelled 
water study. European Journal of Clinical Nutrition. 2003;57(2):279–84.  
299. Fagerland MW, Eide GE, Laake P. Linear regression. In: Veierød MB, 
Lydersen S, Laake P, editors. Medical statistics. 1st ed. Gyldendal Akademisk; 
2012.  
300. Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et 
al. Control of Confounding and Reporting of Results in Causal Inference 
Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical 
Care Journals. Ann Am Thorac Soc. 2019 Jan;16(1):22–8.  
301. Gran JM, Stigum H, Håberg SE, Aalen OA. Causal Inference. In: Veierød MB, 
Lydersen S, Laake P, editors. Medical statistics. 1st ed. Gyldendal Akademisk; 
2012.  
302. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary 
adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–95.  
303. Gustafson P, Le ND. Comparing the Effects of Continuous and Discrete 
Covariate Mismeasurement, with Emphasis on the Dichotomization of 
Mismeasured Predictors. Biometrics. 2002 Dec;58(4):878–87.  
 105
304. Gelman A, Loken E. The garden of forking paths: Why multiple comparisons 
can be a problem, even when there is no “fishing expedition” or “p-hacking” 
and the research hypothesis was posited ahead of time [Internet]. Department of 
Statistics, Columbia Uni- versity. 2013. Available from: 
http://www.stat.columbia.edu/gelman/research/ unpublished/p_hacking.pdf 
305. Bennette C, Vickers A. Against quantiles: categorization of continuous 
variables in epidemiologic research, and its discontents. BMC Med Res 
Methodol. 2012;12:21.  
306. Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 
2014;29(7):1060–4.  
307. Lash TL. The Harm Done to Reproducibility by the Culture of Null Hypothesis 
Significance Testing. Am J Epidemiol. 2017;186(6):627–35.  
308. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. 
Statistical tests, P values, confidence intervals, and power: a guide to 
misinterpretations. European Journal of Epidemiology. 2016;31(4):337–50.  
309. Wasserstein RL, Lazar NA. The ASA’s Statement on p-Values: Context, 
Process, and Purpose. Am Stat. 2016;70(2):129–33.  
310. Gelman A, Stern H. The Difference Between “Significant” and “Not 
Significant” is not Itself Statistically Significant. Am Stat. 2006;60(4):328–31.  
311. Amrhein V, Korner-Nievergelt F, Roth T. The earth is flat (p > 0.05): 
significance thresholds and the crisis of unreplicable research. PeerJ. 
2017;5:e3544.  
312. Amrhein V, Trafimow D, Greenland S. Inferential Statistics as Descriptive 
Statistics: There Is No Replication Crisis if We Don’t Expect Replication. Am 
Stat. 2019;73(sup1):262–70.  
313. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 
1995;311(7003):485.  
314. Wasserstein RL, Schirm AL, Lazar NA. Moving to a World Beyond “ p < 
0.05”. Am Stat. 2019;73(sup1):1–19.  
315. Tong C. Statistical Inference Enables Bad Science; Statistical Thinking Enables 
Good Science. Am Stat. 2019;73(sup1):246–61.  
 106
316. Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 
Clearance Enzyme. Trends Endocrinol Metab. 2017;28(5):340–53.  
317. Fang L, Zhang M, Li Y, Liu Y, Cui Q, Wang N. PPARgene: A Database of 
Experimentally Verified and Computationally Predicted PPAR Target Genes. 
PPAR Res. 2016;2016.  
318. Hannibal L, DiBello PM, Jacobsen DW. Proteomics of vitamin B12 processing. 
Clin Chem Lab Med. 2013;51(3):477–88.  
319. Kim J, Hannibal L, Gherasim C, Jacobsen DW, Banerjee R. A human vitamin 
B12 trafficking protein uses glutathione transferase activity for processing 
alkylcobalamins. J Biol Chem. 2009;284(48):33418–24.  
320. Stolzenberg-Solomon RZ, Miller ER, Maguire MG, Selhub J, Appel LJ. 
Association of dietary protein intake and coffee consumption with serum 
homocysteine concentrations in an older population. Am J Clin Nutr. 
1999;69(3):467–75.  
321. Assies J, Mocking RJ, Lok A, Ruhe HG, Pouwer F, Schene AH. Effects of 
oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and 
cardiovascular disease comorbidity. Acta Psychiatr Scand. 2014;130(3):163–80.  
322. Beaton GH, Burema J, Ritenbaugh C. Errors in the interpretation of dietary 
assessments. Am J Clin Nutr. 1997;65(4):1100S–7S.  
323. Shaw PA, Deffner V, Keogh RH, Tooze JA, Dodd KW, Küchenhoff H, et al. 
Epidemiologic analyses with error-prone exposures: review of current practice 
and recommendations. Ann Epidemiol. 2018;28(11):821–8.  
324. Carroll RJ, Midthune D, Subar AF, Shumakovich M, Freedman LS, Thompson 
FE, et al. Taking advantage of the strengths of 2 different dietary assessment 
instruments to improve intake estimates for nutritional epidemiology. Am J 
Epidemiol. 2012;175(4):340–7.  
325. Freedman LS, Kipnis V, Schatzkin A, Tasevska N, Potischman N. Can we use 
biomarkers in combination with self-reports to strengthen the analysis of 
nutritional epidemiologic studies? Epidemiol Perspect Innov. 2010;7(1):2.  
326. Freedman LS, Tasevska N, Kipnis V, Schatzkin A, Mares J, Tinker L, et al. 
Gains in statistical power from using a dietary biomarker in combination with 
 107
self-reported intake to strengthen the analysis of a diet-disease association: an 
example from CAREDS. Am J Epidemiol. 2010;172(7):836–42.  
327. O’Connell TM, Jia W. Metabolomics. In: Erdman JW, Macdonald IA, Zeisel 
SH, editors. Present knowledge in nutrition. 10th ed. John Wiley & Sons, Inc.: 
International Life Sciences Institute; 2012.  
328. Dahabreh IJ, Hayward R, Kent DM. Using group data to treat individuals: 
understanding heterogeneous treatment effects in the age of precision medicine 
and patient-centred evidence. Int J Epidemiol. 2016 Nov;45(6):dyw125.  
329. Toro-Martín J de, Arsenault B, Després J-P, Vohl M-C, De Toro-Martín J, 
Arsenault BJ, et al. Precision Nutrition: A Review of Personalized Nutritional 
Approaches for the Prevention and Management of Metabolic Syndrome. 
Nutrients. 2017;9(8):913.  
330. Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at - but don’t 
believe them! Curr Control Trials Cardiovasc Med. 2000;1(1):25.  
331. Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to Use a Subgroup 
Analysis. JAMA. 2014;311(4):405–11.  
332. Gardner CD, Trepanowski JF, Del Gobbo LC, al. E. Effect of low-fat vs low-
carbohydrate diet on 12-month weight loss in overweight adults and the 
association with genotype pattern or insulin secretion: The dietfits randomized 
clinical trial. JAMA. 2018;319(7):667–79.  
333. McNulty H, Strain JJ, Hughes CF, Ward M. Riboflavin, MTHFR genotype and 
blood pressure: A personalized approach to prevention and treatment of 
hypertension. Mol Aspects Med. 2017;53:2–9.  

I






























uib.no
ISBN: 9788230858080 (print)
9788230867488 (PDF)
